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Hepatitis C virus (HCV) is one of the leading causes of chronic hepatitis, 
cirrhosis and hepatocellular carcinoma (HCC). With an estimated HCV pre-
valence of about 2.35% of the world population and 3 to 4 million persons 
newly infected each year, HCV infection is a serious public health care issue 
worldwide. Hepatitis C virus is a blood-borne virus with primarily parenteral 
mode of transmission. The most common transmission route in Europe, ac-
counting for around 78% of cases, is injection drug use (IDU), which has also 
prevailed in Estonia from the mid-1990s, followed by sexual contacts. The 
number of patients with chronic hepatitis C (CHC) is increasing and is expected 
to be an important cause of premature mortality and may exert an extra burden 
on the health care system in the nearest future.  
In Europe the prevalence of HCV ranges between 0.1 and 3.2% with low 
prevalence in Belgium and higher in Romania. In Estonia up to 1% or even 
more out of 1.34 million inhabitants are infected with HCV. The HCV has been 
classified into 6 major genotypes and a number of subtypes with different 
geographic distributions. In Estonia, like in other Eastern European countries, 
the most predominant HCV subtypes are 1b and 3a.  
Since 2002 therapy with peginterferon alfa-2a/2b (PegIFN) plus ribavirin 
(RBV) has been recognized as the current standard of care (SOC) for chronic 
hepatitis C. The aim of antiviral therapy is the eradication of HCV infection in 
order to prevent the complications of HCV-related liver diseases. The endpoint 
of therapy is a sustained virological response (SVR). The response to antiviral 
therapy strongly depends on HCV genotype. In general, HCV genotypes 2 and 
3 respond better to combination therapy with SVR over 80%, but results still 
remain unsatisfactory for genotype 1 with SVR rate ranging from 40 to 52 %.  
Thus, predicting non-response (NR) is of major interest for both patient 
wellbeing and health care expense. Different pre- and on-treatment host and 
viral factors, as well as treatment-related factors influence treatment outcome in 
HCV-infected patients. Some of them, such as host (age, stage of fibrosis, 
genetics) and viral factors (genotype, viral load, viral kinetics during treatment), 
and adherence to treatment are known with less controversial issues needed for 
further research. Others, like polymorphisms due to amino acid (aa) substitu-
tions in different regions of the HCV genome, including the non-structural 5A 
(NS5A) protein, suggested also as an additional potential predictor of SVR, are 
less studied. The results of different studies on HCV genetics are conflicting 
and not sufficiently clear, especially regarding European patients. 
The SOC for treatment of CHC patients changed in mid 2011. The appea-
rance of new standard “triple therapy” with direct acting antivirals (DAA) has 
led to significant improvements in response rates even for patients infected with 
HCV genotype 1 and has reduced the duration of treatment. However, to date a 
very high cost of these medications might be a barrier for their wide use in  low- 
and middle-income countries. 
11 
The PegIFN plus RBV therapy has been available for treatment of CHC in 
Estonia from 2005 with up to 400 patients treated annually. Regardless the fact 
that from 2014 two DAA, HCV NS3 protease inhibitors (PIs), telaprevir (TVR) 
and boceprevir (BOC), were approved for use in the treatment of genotype 1-
infected patients, dual antiviral therapy has remained the backbone of treatment 
and is less expensive for CHC.   
There are several studies and doctoral theses dealing with the molecular epi-
demiology of HCV infection and the relationship between host genetic factors 
and susceptibility to and clearance of HCV in Estonia (Zusinaite et al 2000, 
2005, Tallo et al 2000, 2007, Huik et al 2013). At the same time, studies 
assessing the efficacy of PegIFN plus RBV therapy and determining the pre-
dictors of treatment response in Estonian patients with CHC are so far lacking.   
For the first time, the current thesis focuses in a detailed manner on the ana-
lysis of different pre- and on-treatment host and viral factors, including poly-
morphism of NS5A regions, which may be associated with treatment outcome 
in Estonian treatment-naive HCV infected patients and which could be used as a 
















4. REVIEW OF THE LITERATURE 
4.1. Hepatitis C virus 
4.1.1. Historical overview 
The steps towards discovering the hepatitis C virus (HCV) began in the mid-
1970s.  
Known before as non-A, non-B hepatitis (NANBH), it was first mentioned 
in 1975 (Alter et al 1975). Novel technologies with the use of recombinant 
DNA led to the isolation of a single small cDNA clone 5-1-1 from a patient 
with NANBH, which was distantly related to flaviviridae, and encoded for a 
protein that binded antibodies only to NANBH virus, which was renamed as 
hepatitis C virus (Choo et al 1989). Further, the structure of the virus genome 
encoding for certain enzyme activities like serine protease, helicase and poly-
merase, was identified (Kato et al 1990).  
Hepatitis C virus belongs to the Flaviviridae family of viruses, which com-
prises at least three distinct genera, i.e. Pestiviruses, Flaviviruses, and Hepaci-
viruses, which currently includes hepatitis C virus and GB virus (Thiel et al 
2005). HCV particles are spherical in shape with a diameter of 50 to 70 nm, 
consist of nucleocapsids (30–35 nm) with multiple copies of core protein con-
taining single – strand RNA, i.e. the HCV genome, and is surrounded by a lipid 
envelope with two anchored viral glycoproteins, E1 and E2 (Figure 1). HCV 
virions are stable at lower temperatures, but become sensitive when exposed to 
high temperatures and different alcohols and antiseptics (Ciesek et al 2010).   
5’UTR 3’UTR 
 
Figure 1. Structure of the HCV genome and particle (Copyright permission from 
Frontiers Media SA, Moriishi et al 2012)  
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4.1.2. Genomic organization and function of HCV proteins 
The HCV genome consists of one 9.6 kb single-stranded positive RNA mole-
cule with a single open reading frame (ORF) flanked by structured 5’ and 3’ 
nontranslated regions (UTR), which are 341 and approximately 230 nucleotides 
(nt) in length, respectively (Choo et al 1991). The 5’UTR contains an internal 
ribosome entry site (IRES), which is essential for cap-independent translation of 
the viral RNA (Rijnbrand et al 2000). The 3’UTR consists of a variable region, 
a poly U tract and a highly conserved 98-nucleotide RNA element essential for 
viral replication (Friebe et al 2002).  
The linear molecule contains approximately 3000 amino acids, which are 
processed by host and viral proteases into 10 individual proteins, including 
structural proteins (core, envelope E1, and E2), hydrophobic short peptide p7 




Besides its role in capsid formation, the core protein can regulate particle as-
sembly, binding and translation of viral RNA (Ait-Goughoulte et al 2006), it 
may be also involved in other processes such as cell signalling, apoptosis, fibro-
sis, lipid metabolism and suppression of host immune responses (Tellinghuisen 
et al 2002, Rehermann 2009). 
The two envelope glycoproteins, E1 and E2, are thought to play a pivotal 
role at different steps in the HCV replicative cycle. There is now strong evi-
dence that they are essential for host-cell entry by binding to receptor(s) and 
inducing fusion with a host-cell membrane (Bartosch et al 2003). Two hyper-
variable regions, HVR1 and HVR2, have been identified in E2 glycoproteins. 
The HVR1 is known as a neutralizing epitope of HCV and together with HVR2 
it modulates E2 binding (Zibert et al 1997).  
The short peptide p7 may act as an ion channel and participate in virus 
assembly and/or release of viral particles (Griffin et al 2003).  
 
Nonstructural proteins 
Among the nonstructural proteins, NS2 is a transmembrane protein with pro-
tease activity, which cleaves NS2-NS3 junction of the polyprotein and can 
inhibit apoptosis (Erdtmann et al 2003).  
The NS3 protein has serine, nucleotide triphosphatase and RNA helicase 
activities. Together with NS4A it constitutes a protease that is important for 
polyprotein cleavage at the NS3/NS4A, NS4A/NS4B, NS4B/NS5A and NS5A/ 
NS5B junctions (Failla et al 1994). The NS3 influences interferon-dependent 
innate cellular host defence by inhibiting certain pathways (Gale 2003, Reher-
mann 2009).    
The NS4A is a cofactor of the NS3 serine protease. It directs NS3 to the 
endoplasmatic reticulum (ER) and increases its stability (Wölk et al 2000). 
The NS4B is a small membrane-associated protein localized in ER and is a 
component of the replication complex (Penin et al 2004). 
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NS5A is a phosphoprotein with multiple and diverse properties. NS5A parti-
cipates in viral RNA replication, modulation of cell signalling pathways, 
pathogenesis and apoptosis regulation, it can interact with other HCV and host 
cell proteins (Rehermann 2009, Yamasaki et al 2012). Interest in this protein 
arose when it was shown that NS5A can bind and inhibit IFNα-inducible 
double-stranded RNA-activated protein kinase, providing molecular explanation 
of HCV resistance to IFN therapy (Gale et al 1997). The NS5A protein is 
variable in length and sequence according to the different genotypes (Le 
Guillou-Guillemette et al 2007). 
The NS5B is a viral RNA dependent RNA polymerase (RdRp) – a key 
enzyme in the viral replication process, responsible first for the synthesis of 
minus-strand RNA from plus-strand RNA template and, further, negative-strand 
RNA serves as a template for the synthesis of plus-strand RNA molecules. 
NS5B is a membrane protein with the “fingers”, “palm” and “thumb” sub-
domains (Penin et al 2004). As a crucial enzyme for viral replication, it repre-
sents an attractive target for development of new antiviral drugs. 
 
4.1.3. Genetic variability of HCV 
The HCV has high genetic diversity, due to the lack of the proofreading activity 
of its RNA dependent RNA polymerase, and high level of viral replication. The 
mean frequency of nucleotide mutations varies from 1.4 × 103 to 1.9 × 103 
substitutions per nucleotide and per year (Ogata et al 1991, Steinhauer et al 
1992). Some of the mutations accumulating during replication are silent or 
synonymous and have no impact on the amino-acid sequence of the viral 
protein. Other, so called non-synonymous mutations lead to changes in the 
protein sequence and to the emergence of variants (Le Guillou-Guillemette et al 
2007). HCV genetic variability is characterized by the appearance of hetero-
geneous but closely related virus particles known as quasispecies (Barten-
schlager et al 2000). The appearance of quasispecies allows HCV to escape host 
immune system’s pressure and can contribute to resistance to IFN and ribavirin 
therapy, which leads to insufficient SVR rate (Wohnsland et al 2007).  
The 5’UTR and the core are highly conservative regions, the non-structural 
regions 2, 3, 5B and the 3’UTR are relatively variable whereas the envelope 
regions E1 and E2 and the NS4 and the NS5A genes exhibit the highest 
sequence diversity (Penin et al 2001, Le Guillou-Guillemette et al 2007).  
Based on sequence variability within the 5’UTR, core, E1 and NS5B regions 
or the complete genome, HCV has been classified into six major genotypes 
designated as 1 to 6, which differ by about 30 percent of their nucleotide se-
quences (Simmonds et al 2005, Chayama et al 2011). Recently a seventh geno-
type has been reported among immigrants from Central Africa (Smith et al 
2014), (Figure 2). Each genotype is actually a mixture of quasispecies with 70% 
homology. 
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Further these genotypes have been classified into at least 67 subtypes, marked 
as a, b, c, d, etc, which have 20–25% sequence difference (Simmonds et al 




Figure 2. Phylogenetic tree of hepatitis C virus. A phylogenetic tree was constructed 
using 184 complete nucleotide sequences obtained from the DDBJ/EMBL/GenBank 
database (Copyright permission from John Wiley & Sons, Chayama et al 2011) 
 
 
Genotypes differ in distribution both by the geographic region and the mode of 
transmission. Genotypes 1, 2 and 3 have worldwide epidemic distribution with a 
high prevalence of genotype 1 followed by 3 and 2 in Europe, Northern Ame-
rica and Japan, while genotypes 4–6 are endemic and prevalent in certain geo-
graphical areas (Esteban et al 2008, Averhoff et al 2012, Sievert et al 2011, 
Chao et al 2011).  
Due to immigration from HCV genotype-endemic areas and movement of 
injection drug users across European and North American borders, genotypes 
4–6 have been registered in these countries as well (Esteban et al 2008, Corn-
berg et al 2011, Averhoff et al 2012, Al Naamani et al 2013).  
Like in most countries of Central and Eastern Europe (Jansons et al 2004, 
Liakina et al 2009, Cornberg et al 2011), mostly genotype 1b prevails in 
Estonia, followed by 3a and 2a (Tallo et al 2000, 2007, Zusinaite et al 2000).  
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The significance of the HCV genotypes is mostly associated with specific 
transmission routes, so genotypes 1a and 3a prevail among IDUs, while 1b and 
2 are associated with blood transfusions and unsafe medical procedures in the 
past (Pawlotsky et al 1995, Esteban et al 2008). Genotypes 4–6 are associated 
with intravenous drug use as well as with transfusions of unscreened blood 
products and unsafe medical manipulations in countries with scarce health 
resources (Khattab et al 2011, Chao et al 2011, Al Naamani et al 2013).  
The significance of genotypes in pathogenesis and disease progression re-
mains controversial. The HCV genotype alone cannot be an independent factor 
of disease progression. However, genotypes are mostly known as a strong 
predictors of treatment response and duration of antiviral therapy (Manns et al 
2001, Fried et al 2002, Hadziyannis et al 2004, Pearlman et al 2007, Shiffman et 
al 2007).  
 
 
4.1.4. Epidemiology and routes of transmission 
The HCV has worldwide distribution, it can occur among persons of all ages, 
genders and races. Nowadays it has been estimated that about 2.35% of the 
global population is infected with HCV, which amounts to 170 million infected 
people (Lavanchy 2011). Central and East Asia and North Africa/Middle East 
are estimated to have high prevalence (>3.5%); South and Southeast Asia, sub-
Saharan Africa, Central, and Southern Latin America, Australasia, and Europe 
have moderate prevalence (1.5% – 3.5%); whereas Asia Pacific, Tropical Latin 
America, and North America have low prevalence (<1.5%) of HCV infection 
(Hanafiah et al 2013).  
In Europe it was estimated that about 9 million people are infected with 
HCV. A low prevalence of 0.1% has been reported from Belgium (Quolin et al 
2007) and a higher prevalence of 3.2% from Romania (Gheorge et al 2010). 
Each year 86,000 people die because of HCV infection and it accounts for about 
60 -70% of hepatocellular carcinoma (HCC) cases and virus-related liver 
transplantation in Europe (Hatzakis et al 2011, Blachier et al 2013). 
In Estonia, notification of hepatitis C started in 1993. Hospitals and family 
doctors report laboratory-confirmed cases of hepatitis C to the national surveil-
lance system for communicable diseases (NAKIS) at the Estonian Health 
Board.  
In Estonia there are no studies reporting the prevalence of HCV infection in 
general population, besides studies in specific populations, like health care 
workers, blood donors, hemodialysis and oncohematological patients and 
inmates (Priimägi et al 2005, Tefanova et al 2005). In general, it was suggested 
that up to 1% or even more out of 1.34 mln of Estonian inhabitants may be 
infected with HCV (Margus et al 2007).    
The transmission routes of HCV infection are: intravenous drug use, which 
has undoubted the highest risk of HCV acquisition (Zaltron et al 2012); non-
intravenous recreational exposure to drugs, i.g. cocaine, by sharing inhalatory 
instrumentation; accidental needle stick exposure among healthcare workers; 
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healthcare procedures even in developed countries (Gutelius et al 2010, Fabrizi 
2013); mother to child vertical transmission (Murakami et al 2012); sexual 
exposure, which is considered to be very low (Tohme et al 2010) and is a matter 
of concern in males who have sex with men (Marongiu et al 2012).  
Nowadays the most common transmission route in European countries, in-
cluding Estonia, is injection drug use accounting for around 78% of all reported 
cases, followed by sexual contacts (ECDC 2013). Due to the asymptomatic 
nature of HCV infection in up to 30% of cases (Zaltron et al 2012) the route of 
transmission and source of infection remain unknown. 
 
 
4.1.5. Control and prevention 
Mandatory control of blood donors and blood products, established by the Com-
mittee for Proprietary Medicinal Products (CPMP) in the 1990-s, by using anti-
HCV tests and later nucleic acid amplification techniques has significantly 
reduced transmission of HCV infection with the residual risk for acquiring HCV 
via blood products ranging from 1 to 40 per 10 million transfusions in European 
countries (ECDC 2010).  
There is no vaccine or post-exposure prophylaxis for HCV. Prevention of 
acute hepatitis C and its sequelae (chronic hepatitis, cirrhosis, HCC) consists of 
primary and secondary activities.  
Primary prevention is aimed to reduce transmission of HCV infection by 
avoiding unnecessary and unsafe injections, unsafe blood products, use of illicit 
drugs and sharing of injection equipment, unprotected sex with HCV infected 
people, tattoos, piercings and acupuncture performed with contaminated equip-
ment (WHO 2013). 
Secondary prevention is aimed at people who are infected with HCV. It con-
sists of education and counseling and provision of antiviral treatment to these 
patients, it also includes vaccination against hepatitis A and B preventing thus 
coinfection and protecting the liver (CDC 2010).  
In Estonia, there exist special national policies of HCV control in blood 
banks and preventing of HCV in health-care settings, but there is no national or 
regional standard or national policy on HCV prevention and no general anti-
HCV screening programme. Only two specific subgroups, blood donors and 
prisoners are screened on a regular basis.  
 
 
4.2. Natural course of HCV infection 
4.2.1. Acute hepatitis C 
Acute hepatitis C virus infection is a short-term illness that occurs within the 
first 6 months after exposure to HCV. The incubation period is variable, around 
7 weeks (range 4–20 weeks) with detectable HCV RNA and anti-HCV within 
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1–2 weeks and 8 weeks, respectively, followed by elevation of serum alanine 
aminotransferase (ALT) 10–30 times of the upper limit at weeks 6–12 before 
onset of clinical symptoms (Hoofnagle 1997). Spontaneous clearance of in-
fection typically occurs within 3 months from infection in 15% of patients 
(Santantonio et al 2008). Such factors, as young age, ethnicity, female gender, 
immune response and host genetics (IL28B CC genotype, CCR5 and CCL5 
haplotypes) can contribute to it (Post et al 2009, Huik et al 2013, Grebely et al 
2014). 
 
4.2.2. Chronic hepatitis C (CHC)  
After acute hepatitis C the disease becomes chronic in up to 85% of all cases. 
Chronic hepatitis C is a continuous inflammation of the liver caused by HCV 
infection persisting over time period from four to six months with failed spon-
taneous viral clearance and with an existence of compatible clinical signs 
(Mauss et al 2014).  
In case of persistent HCV viremia infected liver cells secrete cytokines and 
chemokines that cause migration of nonspecific mononuclears into liver cells 
(Larrubia et al 2008) with development of liver damage. Persistent inflam-
mation activates hepatic stellate cells, myofibroblasts and fibroblasts, which 
cause development of liver fibrosis (Heydtmann et al 2009, Fallahi et al 2012).  
Most patients with chronic infection are asymptomatic or have only mild 
nonspecific symptoms before presenting liver cirrhosis, which may be un-
recognized for a long time and is presented in the form of overt hepatic de-
compensation (Seef 2002).  
Aminotransferase level can vary usually from twice up to 5 times above the 
upper limit of normal, with about one third of patients having normal serum 
ALT. Patients with persistently normal ALT can have advanced liver disease 
(Shiffman et al 2006). 
Approximately in 20–30% of patients the disease can progress over 10–30 
years to liver cirrhosis (Seeff 2002). Such factors as age of acquisition of in-
fection, gender, race, alcohol and/or illicit drugs abuse, co-infection with HIV 
or/and HBV, comorbidities can contribute to disease progression (Chen et al 
2006). Of patients with HCV-related cirrhosis, 1–4% can develop hepatocellular 
carcinoma (HCC) yearly (Seef 2002).  
In Estonia, the surveillance system covers newly diagnosed CHC cases from 
2004 and HCV has been found as the main etiological agent of chronic viral 
hepatitis (Estonian Health Board, annual report).  
The HCV is a hepatotropic virus, but it can also exist in extrahepatic tissues, 
such as bone marrow, central nervous system, endocrine glands, lymph nodes, 
macrophages and skin cells, that might act as a reservoir and play a role in both 
HCV persistence and reactivation (Ferri et al 1993). More than 30 extrahepatic 
manifestations, i.e. concomitant diseases, have been reported during the natural 
course of chronic hepatitis C (Agnello et al 2004). Their appearance is as-
sociated with B-cell hyperactivation and chronic antigenemia (Klenerman et al 
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2012), and as a result of complex dysregulation of the cytokine/chemokine 
network (Fallahi et al 2012). Approximately one third of HCV infected patients 
have at least one extrahepatic manifestation and it may be the first symptom of 
the disease (Cacoub et al 2000). The best documented manifestations are essen-
tial mixed cryoglobulinemia, porphyria cutanea tarda and some others (Zignego 
et al 2007, Monaco et al 2012).  
A relationship between HCV and sarcoidosis has been described (Ramos-
Casals et al 2005, Faurie et al 2010). The prevalence of sarcoidosis in HCV-
infected patients is reported to be 0.1% – 0.2% (Faurie et al 2010). A relation-
ship between sarcoidosis and HCV infection may emerge in 75% of cases due 
to antiviral therapy with IFN-α and ribavirin, or owing to unknown factor(s) 
(Ramos-Casals et al 2005). Sarcoidosis may appear during the treatment or after 
completion of antiviral therapy. In case of sarcoidosis unrelated to HCV treat-
ment, together with the fact that liver granulomas may be presented in the histo-
logical spectrum of chronic hepatitis C, makes several authors speculate that 
chronic persistent HCV infection per se may trigger systemic sarcoidosis (Bon-
net et al 2002, Gaya et al 2003). 
 
 
4.2.2.1. Diagnostics of CHC 
The diagnosis of CHC is confirmed by the presence of both HCV antibodies 
and HCV RNA with compatible clinical signs and liver histology (Mauss et al 
2014). Tests for detection of anti-HCV include the enzyme immunoassay, 
which contains HCV antigens from the core and nonstructural proteins, and the 
recombinant immunoblot assay. Target amplification techniques with either 
polymerase chain reaction (PCR) or transcription-mediated amplification are 
used for HCV RNA qualification, whereas both target amplification and signal 
amplification techniques are implemented for measurement of HCV RNA 
levels. The above mentioned assays are necessary for the diagnosis of HCV 
infection (Ghany et al 2009, EASL 2014). 
Despite the use of some non-invasive methods, like Fibroscan and bio-
chemical markers of fibrosis (Degos et al 2010), transcutaneous liver biopsy 
remains the gold standard for assessment of HCV-related liver disease severity 
with a very low risk of severe complications (WHO 2014). The widely used 
METAVIR score system for assessing histological changes in the liver is very 
advantageous and easy to grade liver changes (Bedossa et al 1996). 
 
4.3. Treatment of CHC 
4.3.1. Goals of antiviral therapy and types of virological response 
Management of chronic CHC is aimed to eradicate HCV infection preventing 
thus the complications of HCV–related morbidity and mortality (Backus et al 
2011, Veldt et al 2007). Therapy with peginterferon alfa (PegIFN) and ribavirin 
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(RBV) was approved as the standard of care (SOC). The endpoint of therapy 
known as a sustained virological response (SVR) (Lindsay 2002, Ghany et al 
2009) is the main criterion of treatment efficacy. The SVR is durable with a 
relapse rate less than 1% (Swain et al 2010).  
During PegIFN/RBV therapy there occur several on-treatment and off-treat-
ment types of virological response (Figure 3): 
a)  rapid virological response (RVR) defined as undetectable HCV RNA at 
week 4 of antiviral therapy; 
b)  early virological response (EVR) with HCV RNA detectable at week 4, un-
detectable at week 12 (complete EVR); 
c)  nullresponse characterized by a decrease of HCV RNA less than 2 log10 at  
12 week of therapy; 
d)  end-of-treatment virological response (EOT) with undetectable HCV RNA 
level at the end of therapy; 
e)  sustained virological response (SVR) defined as HCV RNA negative at  
6 months after completion of treatment.  
f)  relapse (RL) is detectable HCV RNA after completion of therapy in patients 





Figure 3. Patterns of on-treatment and off-treatment virological responses (Copyright 
permission from John Wiley & Sons, Yu 2009) 
 
  
4.3.2. Overview of antiviral treatment 
Interferon alpha (IFN-α) is a naturally occurring cytokine having antiviral, 
immune modulatory and anti-inflammatory properties (Feld et al 2005), it was 
first used in a pilot study in 1986 for the treatment of NANBH (Hoofnagle et al 
1986). It was suggested that interferon stimulates host’s immune system and 
activates interferon stimulating genes (ISGs) (Zeuzem et al 1996). 
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Monotherapy with IFN-α dosed at 3 MU 3 times a week with a 24-week 
duration of therapy showed 6% of SVR (Di Bisceglie et al 1989, Davis et al 
1989). A further step was the adding of ribavirin (RBV), a guanosine analogue 
with a broad spectrum of antiviral activity (Potter et al 1976), to IFN. It was 
proposed that RBV can modulate host immune responses by shifting a Th2 
response in favor of a Th1 phenotype, directly inhibit viral RNA polymerase 
and cause lethal mutagenesis of HCV RNA genomes (Te et al 2007).  
Clinical trials have demonstrated a SVR rate of 13 – 19% with prolongation 
of monotherapy up to 48 weeks; IFN-α combined with RBV for 24 weeks 
allowed to attain SVR in 31% – 35% of patients, and when the therapy was 
prolonged up to 48 weeks, in 38% – 43% (McHutchison et al 1998, Poynard et 
al 1998).  
A significant breakthrough in therapy has been achieved by using of 
PegIFN. Pegylation is a process that allows, by attaching polyethylene glycol 
strands to the interferon molecule, to prolong its half-life. Clinical trials 
demonstrated SVR rates of monotherapy with PegIFNα for 48 weeks to be 
approximately 39% (Zeuzem et al 2000, Lindsay et al 2001). Based on three 
randomised trials, rules were established for using combination with PegIFNα 
plus RBV in treatment for CHC (Manns et al 2001, Fried et al 2002, 
Hadziyannis et al 2004).  
There are two PegIFNs marketed today, PegIFNα-2a (PEGASYS®, Roche) 
and PegIFNα -2b (PEG-Intron®, Merck). Analogous two forms of RBV are 
used: Copegus manufactured by Roche and Rebetol manufactured by Merck 
Sharp and Dohme. 
 
4.3.3. Standard of care for CHC 
Antiviral therapy with PegIFN/RBV was implemented in early 2000s and was 
determined as a SOC for treatment of chronic hepatitis C. It is recommended to 
all treatment-naive patients with compensated HCV-related chronic liver 
disease who are willing to be treated, do not have any serious comorbidities and 
have no contraindication to either medication. SOC is also recommended to 
patients who failed to eradicate HCV after previous therapy with IFN-α with or 
without RBV (Ghany et al 2009, EASL 2014).  
An individualized therapy, known as a response guided therapy with 
PegIFN/RBV based on the genotype, baseline viral load and decrease of HCV 
RNA during weeks 4 and 12 of treatment, has been proposed. It allows, on one 
hand, by avoiding a large number of side effects without loss of efficacy, to 
shorten the duration of treatment, and, on the other hand, by prolongation of 
treatment, to increase SVR rates in particular patient groups.  
According to these algorithms, patients infected with HCV genotypes 1 and 
4 with a low baseline viral load and RVR, can be treated for 24 weeks, and 
patients infected with genotype 2 and 3 with a low baseline viral load and RVR, 
can be treated for only 16 weeks. Patients with detectable HCV RNA at week 4 
(genotypes 2 and 3) and week 12 (genotypes 1 and 4) but negative HCV RNA 
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at week 24, can benefit from treatment prolongation up to 48 and 72 weeks, 
respectively (Ghany et al 2009, EASL 2014, Margus et al 2007). 
In Estonia, IFN-based monotherapy of chronic hepatitis C was introduced in 
1997 and the SOC for treatment of CHC has been available since 2005. The 
treatment of patients is conducted according to the National Guideline on treat-
ment of CHC, which was approved by the Estonian Society of Gastroenterology 
and the Estonian Society for Infectious Diseases in 2006 and updated in 2007, 
2010. Annually around 400 patients with CHC receive antiviral therapy. It is 
100% reimbursed by the Estonian Health Insurance Fund for patients covered 
by health insurance.  
 
 
4.3.4. Direct acting antivirals in treatment of CHC 
Despite the advances in the management of CHC, the present high cost and 
serious side effects of SOC with yet unsatisfactory treatment results in patients 
infected with HCV genotype 1, have encouraged researchers to introduce new, 
more effective agents with favorable safety profiles targeting different sites of 
the virus genome.  
Direct acting antivirals (DAA) are a potentially new class of antiviral drugs 
aimed at both the structural and nonstructural proteins of the HCV genome and 
interfere with viral replication (Poordad et al 2012).  
In 2011 the Federal Drug Agency (FDA) and the European Medicine Agen-
cy (EMA) approved the first-generation protease inhibitors (PIs) boceprevir 
(BOC) and telaprevir (TVR), both targeting HCV NS3/4A serine protease in 
combination with PegIFN/RBV, for treatment of both naïve and experienced 
chronic HCV genotype 1 patients (Ghany et al 2011, EASL 2014). Triple 
therapy has led to improved response rates of 63-75% with better tolerability 
and safety of treatment (Poordad et al 2011, Jacobson et al 2011, Sherman et al 
2011). Despite promising results, this therapy has demonstrated certain limi-
tations, as it is used only for patients infected with HCV genotype 1. The anti-
viral efficacy of PIs is affected by the presence of resistance mutations within 
the targeted NS3 protein (Bartels et al 2013). It still has disappointing results for 
previous prior partial and null response to PegIFN/RBV and especially for 
patients with cirrhosis.  
Facing these challenges, new antiviral drugs, like sofosbuvir, simeprevir, 
daclatasvir, faldaprevir etc, which allow to achieve SVR up to 98% – 100% 
with both interferon-based and interferon-free regimens, are in progress 
(Asselah et al 2013, Gane et al 2013, Zeuzem et al 2013). Pursuing of goals by 
using new classes of antivirals for treatment of CHC, which include improved 
tolerance, high barrier to resistance, pan-genotypic, oral regimen and favorable 
pill burden, short duration and high SVR rate, will be realistic in the near future 
(McGowan et al 2012).  
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4.4. Factors determining treatment response 
4.4.1. Pre-treatment host factors 
Among the pre-treatment factors, ethnicity is associated with treatment respon-
se. Asian patients respond better than patients of other races, with SVR up to 
70% in patients with genotype 1 and 4, about 90% in those with genotype 2 and 
3, and about 80% in those with genotype 6 (Yu et al 2009). Latinos and 
African-Americans have more worser results as compared to Asian and 
Caucasians patients (Melia et al 2011, Rodriguez-Torres 2008).  
Age less than 40 years is associated with favorable treatment response 
(Hadziyannis et al 2004, Bourliere et al 2012). Older patients have a more ad-
vanced liver disease at baseline and higher incidence of adverse events during 
treatment, which lead to premature discontinuation of treatment and lower SVR 
rate (Huang et al 2010). Nevertheless, patients above 50 years of age infected 
with HCV genotype 1, with low baseline HCV RNA viral load and without 
advanced fibrosis, attained SVR rates comparable with those for younger 
patients (Reddy et al 2009). 
Among Asian patients infected with HCV genotype 1, females younger than 
40 years had significantly higher SVR rate than males, treatment results became 
similar at age from 41 to 50 years, and worser at age over 50 (Yu et al 2011). A 
recent real-life European gender-oriented analysis also has failed to demonstrate 
differences in response to PegIFN/RBV therapy between males and females, but 
it has revealed different predictive factors in both gender groups, which could 
contribute to treatment outcomes (Di Marco et al 2013).  
Data about the influence of body mass index (BMI) on treatment response 
are controversial. A recent large European PROPHESYS trial demonstrated that 
lower BMI was significantly associated with higher SVR rate (Marcellin et al 
2012). Obesity (BMI ≥ 30 kg/m2) in patients with CHC was associated with a 
worse response to PegIFN/ RBV therapy and with an increased rate of liver 
steatosis and fibrosis (Hickman et al 2002).  
The presence of advanced liver fibrosis and cirrhosis leads to worser 
treatment response with SVR rates about 51%–31% and 33%–10%, respecti-
vely (Cheng et al 2010, Bruno et al 2010). The underlying mechanisms of this 
are not well understood (D’Ambrosio et al 2012). Liver steatosis has been 
reported as an unfavorable predictor of treatment response to PegIFN/RBV 
(Leandro et al 2006). The frequency of steatosis in chronic HCV infected 
patients was reported to be around 55%, being higher in patients with genotype 
3 infection, in particular (Savvidou et al 2012).  
Pre-treatment levels of liver enzymes can correlate with treatment response 
in HCV-infected patients receiving therapy with PegIFN/RBV. Low pre-
treatment gamma glutamyl transferase (GGT) level has been associated with 
better treatment response (Weich et al 2011). Elevated GGT is supposed to be a 
surrogate marker of advanced fibrosis and high necroinflammatory activity in 
the liver (Silva et al 2004). In contrast, high baseline ALT level is an indepen-
dent predictive factor of better treatment response (McHutchison et al 2009). 
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4.4.1.1. Host genetics 
Several studies have investigated different host genetic factors than can contri-
bute to both the natural history (susceptibility, spontaneous clearance and per-
sistence) and treatment outcomes of HCV infection (Selzner et al 2008, Huik et 
al 2013, Yuan et al 2013). The best studied and recommended for use in clinical 
practice are single-nucleotide polymorphisms (rs12979860 and rs8099917) near 
the IL28B gene on chromosome 19, encoding interferon-lambda-3, which is 
strongly associated with treatment response to PegIFN/RBV in patients infected 
with HCV genotype 1b and to a lesser extent in patients infected with HCV 
genotypes 2 and 3 (Mangia et al 2010, Sarrazin et al 2011). Individuals with the 
CC genotype achieved higher SVR rate as compared to patients with the CT and 
TT genotypes (Ge et al 2009, Par et al 2011, 2014). 
 
4.4.2. Pre-treatment viral factors 
Of the pre-treatment viral factors, virus genotype and viral load are strong 
predictors of treatment response and can determine the duration of antiviral 
therapy (Manns et al 2001, Fried et al 2002, Hadziyannis et al 2004). Of the six 
HCV genotypes found worldwide, genotype 1 is difficult to cure, with SVR 
rates up to 52% (Fried et al 2002, Hadziyannis et al 2004) and even less than 
50% in real-life settings (Mauss et al 2011, Bourliere et al 2012) but up to 80% 
or more for genotypes 2 and 3 (Zeuzem et al 2004). The reasons for this are not 
completely clear.  
Currently, low or high baseline viral load is known as an issue to guide 
treatment decisions (Ghany et al 2009, EASL 2014). Low pre-treatment viral 
load is associated with better treatment response (Marcellin et al 2012). The 
definition of low baseline viral load (LVL) is under discussion, ranging from 
400 000 up to 800 000 IU/ml (Manns et al 2001, Fried et al 2002, Shiffman et al 
2007, Zeuzem et al 2006).  
 
 
4.4.3. On-treatment viral factors 
Undetectable serum HCV RNA at week 4 of therapy, known as RVR, is an 
independent predictor of SVR (Poordad et al 2008). For patients with all 
genotypes, who achieve RVR, the probability of attaining SVR is 88–100% 
(Fried et al 2011). Achievement of RVR together with low baseline viral load is 
a decision point for shortening treatment duration from 48 weeks to 24 weeks in 
about 15% of patients infected with HCV genotype 1 (Zeuzem et al 2006) and 
from 24 to 12–16 weeks in patients infected with HCV genotype 2 and 3 
(Shiffman et al 2007).  
Another important time and decision point is week 12, known as a stopping 
rule for patients infected with HCV genotype 1. The EVR with undetectable 
HCV RNA or a > 2 log10 drop in viral load allows to attain SVR in 68–84% and 
17–29% of genotype 1 patients, respectively (Berg et al 2006). Patients infected 
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with HCV genotype 1 who have failed to achieve EVR should stop 
PegIFN/RBV therapy, because the probability of attaining SVR is very low 
(Fried et al 2002). About 20% of patients infected with HCV genotype 1, (Berg 
et al 2006) determined as “slow” virological responders, i.e. HCV RNA 
detectable at week 12 with > 2log10 decline in viral load and HCV RNA nega-
tive at week 24, may benefit from extended treatment duration from 48 to 72 
weeks (Pearlman et al 2007). Patients infected with HCV genotype 2 and 3 with 
EVR and negative cofactors, like advanced fibrosis or cirrhosis and high 
baseline viral load, can benefit from prolongation of treatment up to 48 and 
even 72 weeks (Hadziyannis et al 2004).  
 
4.4.4. Treatment related factors 
Adherence to PegIFN/RBV therapy is another important issue determining 
treatment outcome. Following the rule, defined as taking no less than 80% of 
the total dose of PegIFN and/or no less than 80% of total RBV dose and/or 
during no less than 80% of the total period of treatment, is crucial for achieving 
SVR (McHutchinson et al 2002). For patients infected with HCV genotype 1b, 
who take less than 60% of each medication SVR rate is only 7.7%, versus 31% 
for those who take more than 60% of each medication (Arase et al 2007).  
Patient education and close cooperation with medical staff in centres with 
higher experience (>15 patients/year treated) and facilities, as well as certain 
host and viral factors (male gender, age, genotype and IFN dosage) allow to 
enhance adherence to therapy with PegIFN/RBV (Tanioka et al 2009).    
 
 
4.4.5. Adverse events of antiviral therapy 
During PegIFN/RBV therapy adverse events (AE), similar equal for both 
PegIFNα-2a and 2b, have been observed. As a result, patients experience im-
paired quality of life (Björnsson et al 2009), they are obliged to reduce the dose 
of drugs and about 10–15% of patients in clinical trials and even a higher 
percentage in real-life settings discontinue antiviral therapy.  
Premature discontinuation leads to significantly lower SVR rate for patients 
compared with those who only reduced medication doses (Arase et al 2007). 
The most common AE are hematologic (anemia, leuco-, neutro- and thrombo-
cytopenia), dermatologic (alopecia, dermatitis, pruritis, injection site reaction), 
neuropsychiatric (depression, polyneuropathy, convulsions), endocrinological 
(hypo- or hyperthyroidism), gastrointestinal (nausea, anorexia, abdominal pain, 
dyspepsia, constipation), pulmonary (cough and/or dyspnea, interstitial pneu-
monitis), cardiovascular (myocardial ischemia), and ocular (retinopathy) (Sul-
kowski et al 2011, Monaco et al 2012).  
Appropriate monitoring and medical management of treatment-related AE 
can enhance SVR rate (Sulkowski et al 2011). Step-down strategy of continuous 
reduction of both PegIFN and RBV until absolute discontinuation is used in the 
case of hematological abnormalities (Ghany et al 2009, EASL 2014). Several 
26 
adjuvant growth factors, such as epoetin α for treatment of anemia, and 
filgastrim and eltrombopag for treatment of neutro- and thrombocytopenia, 
which can enhance the SVR rate, are in use (Sulkowski et al 2011).  
 
 
4.5. Structural polymorphism within the entire HCV 
NS5A region and treatment response 
The mechanism of resistance to antiviral treatment in patients infected with 
HCV genotype 1 is not thoroughly understood. In order to explain the influence 
of the viral factor on the efficacy of IFN-based therapy, polymorphisms due to 
amino acid substitutions within the non-structural 5A protein (NS5A; aa 1973-
2419) (Figure 4) have been the main focus in a number of studies (Bouzgarrou 
et al 2009, Noguchi et al 2011, Muñoz de Rueda et al 2008, Chayama et al 
2011, Jardim et al 2009, 2013). Currently, these polymorphisms have been 
described in terms of a number of random mutations making the sequence 
divergent from the prototype (Muñoz de Rueda et al 2008, El-Shamy et al 
2008). The prognosis for therapy outcome is suggested to be as good as many 





Figure 4. Location of different regions of interest within HCV NS5A protein 




The first positive correlation between number of mutations in the interferon 
sensitivity determining region (ISDR; aa 2209-2248) within the NS5A protein 
and SVR rate in Japanese patients infected with genotype 1b was described by 
Enomoto et al in 1995. Thus, patients infected with the wild type ISDR 
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sequence (identical to the prototype Japanese HCV strain, HCV-J) did not 
respond to IFN-based therapy, whereas patients infected with the mutant type, 
defined as four or more amino acid substitutions in this region, achieved SVR. 
Following studies from Japan also confirmed those results (Okanoue et al 2009, 
Watanabe et al 2005, Maekawa et al 2009) while studies from Europe (Veillon 
et al 2004, Kmieciak et al 2006, Brillet et al 2007) and the United States (Nous-
baum et al 2000, Murphy et al 2002) failed to distinguish correlation between 
ISDR mutations and SVR.  
The clinical importance of mutations within the protein kinase-binding do-
main (PKR-bd; aa 2209-2274), was investigated and PKR-independent effects 
of NS5A in the IFN response have been also proposed. Concerning the other 
NS5A regions, significant correlation has been reported between sequence 
variation in the variable domain (V3; aa 2356-2379) or its upstream region near 
the carboxy terminus of NS5A, referred to as the IFN/RBV resistance-
determining region (IRRDR; aa 2334-2379), and response to INF based therapy 
(Duverlie et al 1998, Murphy et al 2002, Sarrazin et al 2002, Hofmann et al 
2005). The mean number of aa substitutions in the V3 region and in IRRDR 
was significantly higher for HCV isolates obtained from SVR patients 
compared with non-SVR patients (El-Shamy et al 2008). The significance of 
these mutations has been also confirmed by studies carried out in different 
populations of different countries (Kumthip et al 2011, Yano et al 2012). 
Treatment response may be associated also with some specific aa sub-
stitutions of NS5A. Thus, it has been demonstrated that patients infected with 
HCV genotype 1b who had aa mutations in NS5A at positions 2209, 2216, 
2217, 2218, 2227, 2360, and 2378 (according to the numeration of the HCV-J 
prototype strain) achieve SVR more frequently than those without mutations at 
these positions (Kohashi et al 2006, Muñoz de Rueda et al 2008, El-Shamy et al 
2008, Noguchi et al 2011). 
But the influence of HCV intragenotypic variability on the combination 










5. AIMS OF THE STUDY 
The main objective of the study was to assess the efficacy of PegIFN/RBV the-
rapy in Estonian treatment-naïve patients with CHC in relation to different host 
and viral factors, including polymorphisms within the entire NS5A region of the 
HCV genome.  
 
The aims of the study were:   
1. To study the efficacy of peginterferon alfa-2α and ribavirin therapy in 
treatment-naïve patients with chronic hepatitis C genotype 1 and 3 infections 
(Paper I and II). 
2.  To determine pre-treatment and on-treatment host and viral factors as-
sociated with peginterferon alfa-2α and ribavirin therapy outcome in chronic 
hepatitis C genotype 1b patients (Paper III). 
3.  To assess the genetic variability of the non-structural (NS5A) protein of the 
HCV and its association with peginterferon alfa-2α and ribavirin therapy 





















6. MATERIALS AND METHODS 
6.1. Study subjects 
The study population consisted of the treatment-naïve monoinfected patients 
with chronic hepatitis C referred to a gastroenterologist of the Internal Medcine 
Clinic of West-Tallinn Central Hospital (WTCH) between February 2005 and 
March 2011. 
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Figure 5. Flow chart of the studied patients. 
 
Additionaly, we present one case report exemplifying relationship between 
systemic sarcoidosis and chronic hepatitis C in a patient infected with HCV 
genotype 1b from study 1. 
The diagnosis of CHC was based on the presence of anti-HCV antibodies 
and HCV RNA in the sera, histologically verified fibrosis stage and degree of 
inflammatory activity and clinical follow-up.  
The exclusion criteria for treatment were age <18 years, chronic alcohol in-
take, decompensated cirrhosis, current injection drug use, depression, co-in-
fections with HIV and HBV, and severe comorbidities (poorly controlled hyper-
tension, heart failure, diabetes and chronic obstructive pulmonary disease).  
The treatment decision and further management of patients were conducted 
according to the Estonian National Guidelines on the treatment of CHC.  
Written informed consent for the use of clinical data and serum samples was 
obtained from all patients prior to the study.  
The study was approved by the Tallinn Medical Research Ethics Committee, 
protocol No.1130. 
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6.2. Study methods 
6.2.1. Laboratory and clinical investigations 
Complete blood count, ALT, AST, GGT, ALP, bilirubin, TSH, and autoanti-
bodies (ANA, AMA M2, ASMA, LKMA) were measured before the start of 
therapy. Complete blood count and liver enzymes were measured in the blood 
taken from the cubital vein every four weeks during the treatment period and 
TSH was measured at weeks 12, 24, 36 and 48. Blood tests were performed in a 
clinical laboratory at WTCH.  
Patient’s height and weight were measured and body mass index (BMI) 
before treatment was calculated. Antibodies to HCV in serum prior to treatment 
were determined by a Abbott HCV EIA 2.0 (Abbott Laboratories, Abbott Park, 
IL) enzyme immunoassay before 2010 and thereafter by the electrochemi-
luminescence immunoassay Anti – HCV II test (Roche Diagnostics GmbH). 
Serum HCV RNA level before therapy and at weeks 4, 12, 24, and at the end of 
therapy at 24 or 48 weeks, and 24 weeks after treatment were analysed by a 
quantitative PCR assay. The COBAS Amplicor HCV Monitor version 2.0 test 
(lower detection limit of 50 IU/ml) was used in 2005–2009 and the COBAS® 
AmpliPrep/COBAS® TaqMan HCV test (lower detection limit of 15 IU/mL, 
the linear range of the assay 43 to 69,000,000 IU/mL) was used from 2010.  
HCV genotypes were determined by the hybridization technique using a 
VERSANT HCV genotype assay (LiPA), Bayer Health-Care LLC, Tarrytown, 
NY.  
Antibodies to HCV, HCV RNA measurements and the genotyping assays 
were performed in the Laboratory of HIV Diagnostics of WTCH. 
During clinical visits physical examination was performed with evaluation of 
adverse events and use of concomitant medications.  
 
 
6.2.2. Transcutaneous liver biopsy and histology 
Ultrasound-guided transcutaneous liver biopsy was performed to all patients at 
baseline by the author of the thesis at the Department of Radiology of West-
Tallinn Central Hospital. 
Liver biopsies were assessed by using Metavir score in Pathology Centre of 
North Estonia Medical Centre. Stage of fibrosis was scored as follows: F0, no 
fibrosis; F1, portal fibrosis without septa; F2, portal fibrosis with rare septa; F3, 
numerous septa without cirrhosis, and F4, cirrhosis. Degree of inflammation 
was scored from 0 to 3 with A0 representing absent activity, A1 minimal, A2 
moderate and A3 severe activity (Bedossa et al 1996). 
 
 
6.2.3. HCV RNA extraction and cDNA synthesis 
HCV RNA was extracted from 200 μl of pre-treatment serum using the TriPure 
isolation reagent (Roche Diagnostics GmbH, Mannheim, Germany) according 
31 
to the manufacturer’s recommendations. The extracted RNA was reverse 
transcribed and amplified for full-length NS5A using SuperScript III reverse 
transcriptase (Invitrogen, Waltham, USA) and random primers (Fermentas, 
Vilnius, Lithuania) according to the manufacturer’s instructions.  
 
 
6.2.4. Entire NS5A amplification, sequencing and  
phylogenetic analysis 
The entire NS5A gene (1341nt/ 447 amino acids; aa) was amplified with 
external primers 5’-ATGAACCGGCTGATAGCGTT-3’ and 5’-CTCCTTGAG 
CACGTCCCGGT-3’ and internal primers 5’-TCCCCCACGCACTATGTGCC-
3’and 5’-CGGTARTGGTCGTCCAGGAC-3’. The PCR products were se-
quenced directly with the PCR internal primers used for amplification and 
primer 5’-ATTCCAGGTCGGGCTCAA-3’. The obtained sequences were 
edited with the BioEdit v7.0.8.0 software and aligned with the NS5A region of 
HCV-J prototype for genotype 1b (GenBank accession number D90208) with 
the ClustalW multiple alignment utility. Phylogenetic analysis was carried out 
using the MEGA software (http://www.megasoftware.net) using the Kimura-2 
parameter model. The phylogenetic tree was constructed by the maximum like-
lihood (ML) method using the MEGA 5.2 program. Bootstrap analysis was 
performed on 1000 replicates.  
All sequences reported herein were deposited in the National Center for 
Biotechnology Information (NCBI) GenBank nucleotide sequence databases 
with accession numbers JX022751-JX022779.  
 
 
6.3. Peginterferon alfa-2a and ribavirin treatment 
Treatment of the study patients was conducted by the author of the thesis in 
accordance to National Guideline on the treatment of CHC. All patients, de-
pending on the genotype, were administered 24 or 48 weeks of SOC.  
PegIFN alfa-2a/PegIFN (Pegasys, F. Hoffmann La Roche Ltd, Basel, 
Switzerland) was administered at a dosage of 180 μg/week. The RBV (Co-
pegus, F. Hoffmann La Roche Ltd, Basel, Switzerland) was given per os at a 
dosage of 1200 mg/day or 1000 mg/day, depending on body weight (above or 
below 75 kg), to patients infected with genotype 1b; and at a fixed dosage of 
800 mg/day, regardless of body weight, to patients infected with genotype 3a. 
Response-guided treatment algorithms for patients infected with HCV geno-
types 1b and 3a are presented in Figures 6 and 7.  
Before starting antiviral therapy a nurse demonstrated to all patients how to 
inject subcutaneously PegIFN. 
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Week 0                        Treatment with Pegasys  180 μg s/c once weekly
plus Copegus 1200 mg/day (>75 kg) or 1000 mg/day (≤75 kg)
Week 4                        HCV RNA negative                  HCV RNA positive
Week 12                      HCV RNA negative                 HCV RNA positive
if < 2 log drop           stop therapy 
if > 2 log drop
Week 24                                        HCV RNA negative HCV RNA positive        stop therapy
if LVL        
stop therapy EOT
Week 48 EOT                   HCV RNA negative                  HCV RNA positive            NR
Week 72                            HCV RNA negative          SVR HCV RNA positive            RL
 
Figure 6. Treatment algorithm for patients infected with HCV genotype 1b. Adopted 
from the Estonian National Guidelines on treatment of CHC, 2007, 2010. 
Week 0                                 Treatment with Pegasys 180 μg once weekly
plus Copegus 800 mg pro die independently of weight
Week 4                                HCV RNA negatiivne        HCV RNA positive
if LVL             if LVL
Week 16  EOT        HCV RNA negative     
Week 24 EOT                                        HCV RNA negative                   HCV RNA postive       NR
Week 48                                                HCV RNA negative                    HCV RNA positive
SVR                                              RL
 Figure 7. Treatment algorithm for patients infected with HCV genotype 3a. Adopted from the Estonian National Guidelines on treatment of CHC, 2007, 2010.  
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Modifications and changes in PegIFN alfa-2a doses were made according to 
recommendations of the product manufacturer in the face of appearance of 
blood abnormalities and adverse events during antiviral therapy. If the value of 
leucocytes appeared to be below 1.5 × 109/l, the value of neutrophils below  
0.75 × 109/l and the value of platelets below 50x109/l the dose of PegIFN alfa-
2a was reduced to 90 μg/week. When blood abnormalities progressed with 
leuco- neutro- and thrombocytopenia below 1.0 × 109/l, 0.5 × 109/l and 25 × 
109/l, respectively, treatment was stopped.  
The dose of RBV was modified according to recommendations of the pro-
duct manufacturer depending on the hemoglobin (Hgb) profile: if Hgb level fell 
below 100 g/l the RBV daily dose was reduced to 600 mg/day and stopped if 
the Hgb level was below 85 g/l. Also the doses of both medications were 
modified and even stopped if the studied patients experienced adverse effects or 
intolerance of antiviral therapy. Treatment outcomes were assessed as SVR, 
non-response and relapse.  
 
  
6.4. Statistical analysis 
For statistical analysis, the χ2 test, Fisher’s exact test and Student’s t-test were 
used. A two-tailed P value of less than 0.05 was considered statistically signi-
ficant. 
Quantitative variables are expressed as mean ± SD. 
Both univariate (Paper III) and multivariate (Paper I) logistic-regression ana-
lyses with calculations of odds ratios (OR) and confidence intervals (CI) were 
performed to explore the baseline factors that could predict the treatment 
outcomes.  
Confidence intervals (CI) are 95% (Paper I, III, IV). 
Comparisons between the groups were made by the Student’s t-test or the 
Mann-Whitney test for quantitative variables and the chi-square or Fisher’s 
exact test for categorial variables. 
Correlation between the variables was estimated by Pearson’s or Spearman’s 










7.1. Efficacy of PegIFN alfa-2a and RBV treatment in 
patients with genotypes 1b and 3a (Papers I and II) 
To estimate the efficacy of PegIFN alfa-2a and RBV therapy in Estonian 
treatment-naïve patients with CHC, a total 121 outpatients aged 19–63 years (76 
infected with HCV genotype 1b and 45 with genotype 3a, mean age 42.7 vs 
35.1 years, respectively, p<0.01) were enrolled in the study (see the flow chart 
in Figure 5).  
At baseline, the viral load in 75.2% (91/121) of the patients was higher than 
600 000 IU/ml. Histologically, 88.4% (107/121) of the patients had fibrosis 
score F0 – 2, 11.6% (14/121) had advanced fibrosis, F3-4 (Paper I, Table 1).  
The overall SVR rate in this setting was 60.3%, being statistically lower in 
patients with HCV genotype 1b, as compared with genotype 3a patients, 46.1% 
(35/76) vs. 84.4% (38/45), respectively, (p=0.0004).  
The overall non-response and relapse rates were 13.2% (16/121) and 12.4% 
(15/121), respectively, being significantly higher for patients infected with 
genotype 1b compared with patients infected with genotype 3a 19.7% (15/76) 
vs. 2.2% (1/45), p=0.01 and 17.1% (13/76) vs. 4.4% (2/45), p=0.04, respect-
tively (Table 2). 
 
 






n = 76 
Genotype 3a, 
n = 45 
All patients, 
n = 121 
p-value* 
SVR, n (%) 
 
 
 35 (46.1) 38 (84.4) 73 (60.3)  0.0004 
Non-response, n (%) 
 
15 (19.7) 1 (2.2) 16 (13.2)    0.01 
Relapse, n (%) 
 
 
13 (17.1) 2 (4.4) 15 (12.4)    0.04 
Discontinued treatment, 
n (%) 
13 (17.1) 4 (9.0) 17 (14.1)    0.282 
 
 
In the present study patients with the viral load below 600 000 IU/ml had higher 
SVR as compared to patients with the viral load above 600 000 IU/ml, 73.3% 
(22/30) vs. 57.4% (35/61), respectively, but the difference did not reach signi-
ficance (p=0.25). Nor was there found significant correlation of SVR with base-
line levels of HCV RNA depending on the genotype (p=0.33).  
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The SVR rate was higher in patients younger than 40 years compared with 
older patients (> 40 years), 76.4% (42/55) vs. 47.0% (31/66), regardless of the 
genotype (p<0.01).  
Allthough females had higher SVR rate than males, 68.7% (33/48) vs. 54.8% 
(40/73), respectively, the difference between the genders was not statistically 
significant (p=0.13). 
The SVR rate for the studied patients with the fibrosis score 0-1 and for the 
patients with the fibrosis score 2-3 did not differ significantly, being 64.8% 
(59/91) and 66.7% (14/21), respectively (p=0.09). None of the studied patients 
with cirrhosis (F4), eight patients infected with genotype 1b and one patient 
with genotype 3a, achieved SVR. 
To determine the independent predictors of achieving SVR, such factors, 
like genotype, age, viral load, stage of fibrosis, and gender, were analysed by 
multivariate logistic regression analysis. It revealed only two factors that 
increased the odds of achieving SVR independently and significantly: HCV 
genotype 3 (OR 6.359; CI 2.525−16.017, p<0.0001) and patient’s age 40 years 
or less (OR 0.274; CI 0.125−0.603, p=0.0014). Such variables as pretreatment 
viral load, fibrosis score or male gender did not correlate significantly with SVR 
rate, according to this analysis.  
In our study 96.7% (117/121) of the patients experienced several adverse 
events shown in Table 3. 
 
 
Table 3. Adverse events in the studied patients during PegIFN/RBV therapy 
 
 Genotype 1, 
n = 76 
Genotype 3. 
n = 45  
All patients, 
n = 121 
p-value  
Fatigue, n (%) 70 (92.1) 39 (86.7) 109 (90.1) 0.359 
Leucopenia, n (%) 61 (80.2) 35 (77.8) 96 (79.3) 0.878 
Neutropenia, n (%) 64 (84.2) 32 (71.1) 96 (79.3) <0.05 
Anaemia, n (%) 31 (40.8) 12 (26.7) 43 (35.5) <0.05 
Depression, n (%) 19 (25.0) 11 (24.4) 30 (24.8) 0.563 
 
 
Patients infected with genotype 1b experienced more often adverse events than 
patients infected with genotype 3a, but only neutropenia and anaemia differed 
significantly, 84.2% (64/76) vs. 71.1% (32/45), p<0.05 and 40.8% (31/76) vs. 
26.7% (12/45), p< 0.05, respectively. However, as adverse events were ge-
nerally mild and the rate of treatment discontinuation was therefore low, they 
did not influence significantly SVR rate.  
Seventeen patients out of 121 (14.0%) discontinued antiviral treatment. 
Eight patients, of these 7 with genotype 1b and one with 3a genotype, stopped 
treatment because of adverse events. Nine patients (7 with genotype 1b and 2 
with genotype 3a) were lost to follow-up for various reasons at different weeks 
(4 weeks to 48 weeks) of antiviral therapy.  
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Adherence to PegIFN/RBV therapy, as assessed on the basis of self-reports 
during visits, was high, only thirteen of the 76 patients (17.1%) infected with 
HCV genotype 1b required dose reduction in PegIFN alfa-2a and/or RBV be-
cause of adverse events.  
Nevertheless, nine of them (69%) followed the rule of 80% (McHutchinson 
et al 2002) and achieved SVR (Figure 8).  
Neutropenia below 0.75 × 109/l and haemoglobin level <100 g/l were the 
main reasons for dose reduction in both medications.  
13 patients infected with HCV genotype 1b, who reduced
the doses of PegIFN and/or RBV
3 patients, who discontinued treatment prematurely            SVR
(1 at week 24 and 2 at week 44)
6 patients, who continued treatment until the end                 SVR
3 patents, who stopped treatment earlier                               NR
(2 at week 12 and 1 at week 48) 
1 patient, who discontinued treatment                             lost to
because of intolerance of therapy                                    follow-up
 
Figure 8. Flow chart of the patients infected with HCV genotype 1b, who reduced the 
doses of PegIFN and/or RBV.  
 
 
Out of the 121 study patients, extrahepatic manifestations were diagnosed only 
in two of them: one had mixed cryoglobulinemia and the other had systemic 
sarcoidosis. A 25-year-old man, infected with HCV genotype 1b, and with 
moderately elevated liver enzymes was referred to the gastroenterologist at the 
WTCH in March 2009. Antiviral treatment was offered, but the patient decided 
to start it later. Four months later, there developed pulmonary symptoms and 
erythema nodosum of the left leg. Computer tomography (CT) scans of the 
chest showed mediastinal and hilar adenopathy and focal lesions in the right 
upper lung lobe. Transbronchial biopsy of pulmonary lymph nodes revealed 
epithelioid cell granulomas. Systemic sarcoidosis was diagnosed and corti-
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costeroid treatment with prednisolone 20 mg orally was started. After one 
month of corticosteroid therapy the skin lesions disappeared and the patient dis-
continued treatment by himself. Three months later transcutaneous liver biopsy 
was done which revealed hepatic granulomas. Chronic hepatitis C with co-
existence of pulmonary and hepatic sarcoidosis was diagnosed. The patient 
started and completed a 48-week course of PegIFN/RBV therapy. The patient 
achieved SVR with no reactivation of systemic sarcoidosis. Transcutaneous 
liver biopsy performed 5 months after SVR showed no remnant granulomas 
specific for sarcoidosis.  
 
 
7.2. Predictors of treatment response in patients infected 
with HCV genotype 1b (Paper III) 
7.2.1. Baseline host and viral factors and treatment response 
Pre-treatment and on-treatment host and viral factors that are associated with 
PegIFN/RBV therapy outcome in 76 treatment-naïve patients, 44 males and 32 
females, mean age of 43.0 years, with chronic hepatitis C genotype 1b, were 
described in Paper III. The baseline characteristics of the studied patients are 
shown in Table 1 (Paper III).  
According to treatment response, 38 (50%) out of the 76 studied patients 
achieved SVR, whereas the remaining 38 (50%) patients did not and were 
referred to as non-SVR. Of the non-SVR patients 18 (23.7%) were non-
responders (NR), i.e. patients in whom serum HCV RNA level remained stable 
during treatment, and 15 (19.7%) were relapsers (RL), i.e. patients who sero-
reverted to HCV RNA during 6 months of follow-up. All patients with SVR and 
8 of the 15 (53.3%) RL patients achieved complete EVR, while only 6 of the 18 
(30%) NR and 7 (46.7%) of the RL achieved partial EVR. Five (6.6%) of the 76 
studied patients stopped treatment due to adverse events.  
Five baseline parameters that were associated significantly with high SVR 
rate were identified by univariate logistic regression analysis: age below 40 
years (OR 0.9521; CI 0.9108 – 0.9953, p = 0.0302), normal platelet count (OR 
1.0115; CI 1.0029 – 1.0201, p = 0.0084), normal GGT level (OR 0.9901; CI 
0.9804 – 0.9999, p = 0.0469), absence of or mild and moderate stages of liver 
fibrosis (OR 0.6233, CI 0.4250 – 0.9143, p = 0.0156), and absence of or mild 
inflammatory activity (OR 0.5404, CI 0.3272 – 0.8925, p = 0.0162).  
However, the other factors, like patient gender, BMI, viral load and ALT 
levels were not associated with treatment outcomes in our study (Table 4). 
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Table 4. Comparison of the baseline features in the patients with sustained virological 
response (SVR) and non-SVR. 
 
 SVR (n = 38) Non-SVR (n = 38) P 





22 (57.9)  
16 (42.1)  
 
 
22 (57.9)  





RVR vs nonRVR 6/17 2/17 0.258 
Age, n (%) 
Mean ± SD 
< 40 yrs 




17 (44.7)  
21 (55.3)  
 
 46.1±9.6 
 7 (18.4)  





BMI, n (%) 
Mean ± SD 
≤ 25 kg/m2 




18 (47.4)  
20 (52.6)  
 
27.5±5.3 
12 (31.6)  





Viral load, n (%) 
Mean±SD-log10 IU/ml 
≤ 0.6 mln. IU/ml 













Fibrosis, n (%) 
F 0 – 2 
F 3 – 4 
 
 
36 (94.7)  
  2   (5.3)  
 
27 (71.1)  











  9 (23.6)  
21 (55.3)  
  8 (21.1)  
 
 
  8 (21.1)  
  8 (21.1)  



















ALT, n (%) 
Mean ± SD, U/l 
≤ 42 U/l 




  5 (13.2)  
33 (86.8)  
 
91.8±54.9 
  8 (21.1)  





GGT, n (%) 
Mean ± SD, U/l 
≤ 61 U/l 




25 (80.6)  
  6 (19.4)  
 
91.7±91.6 
16 (51.6)  








The studied variables were then analysed by multivariate logistic regression ana-
lysis, which revealed less significant power of association between them and 
SVR. 
In order to find out the predictors of treatment response, the baseline host 
and viral characteristics for patients with different treatment responses were 
analysed.   
It was found that the NR patients were significantly older (48.3±7.8 years vs. 
39.7±12.0 years, p=0.008), more overweight (28.3±7.8 kg/m2 vs. 25.8± 
4.3 kg/m2, p<0.05), had a more severe stage of fibrosis (F3–4) (38.9% vs. 5.3%, 
p=0.031), and a higher degree of inflammation (77.8% vs. 21.1%, p=0.0002), 
lower platelet count (205.3±66.0×109 U/L vs. 245.1±61.4×109 U/L, p=0.031), 
and higher GGT levels (76.9% vs. 19.4%, p<0.001) compared with the SVR 
patients.  
High grade of inflammatory activity 77.8% vs. 33.4% (p=0.038) and higher 
GGT levels, 76.9% vs. 30.8% (p=0.047) prevailed significantly in the NR in 
comparison with the RL.  
There were no significant differences in the characteristics between the SVR 
and RL patients, while the NR patients differed significantly from the SVR 
patients practically in terms of all studied parameters.  
 
7.2.2. On-treatment host and viral factors and treatment response 
Changes of the on-treatment host factors and changes of the viral load between 
the groups of patients (SVR vs. NR, SVR vs. RL, NR vs. RL) at weeks 4 and 12 
were analysed (Paper III, table 2).  
The SVR patients had a more pronounced decrease of the viral load at weeks 
4 and 12 as compared to both the non-responders and the relapsers (–3.59 and  
–5.98 log10 IU/ml, respectively, p<0.01). Similarly, the RL had a more sig-
nificant decrease of the viral load compared to the NR (–4.89 log10 IU/ml and  
































Figure 9. Viral kinetics of the study patients at baseline, weeks 4 and 12. 
40 
The other parameters such as ALT (p=0.002) and Hgb (p=0.05) levels, leuco-
cyte (p=0.02), and neutrophil (p=0.018) counts were significantly higher for the 
NR patients compared to the SVR and RL patients at week 12. There were no 
differences in these parameters between the SVR, NR and RL patients at week 
4. 
 
7.3. Amino acid polymorphisms within the entire HCV 
NS5A region and treatment response (Paper IV) 
7.3.1. Baseline characteristcs of patients and treatment response 
Twenty-nine pre-treatment serum samples out of 76, obtained from patients 
infected with HCV genotype 1b (Paper III) were analysed for nucleotide and 
amino acid sequences. 
Among the 29 patients enrolled in the study, 18 were male and 11 female 
aged 19 to 60 years, mean age 41.5 years. At baseline, the viral load of 89.7% 
(26/29) of the patients was higher than 600 000 IU/mL. Seventy nine percent 
(23/29) of the patients had fibrosis (F) score 0–2. 
Out of all patients 12 (41.4%) achieved SVR, 15 (55.6%) failed to achieve 
SVR and were referred to as non-SVR. Of the non-SVR patients eight (53.3%) 
were referred to as NR and seven (46.7%) patients were denoted as RL. During 
follow-up two patients stopped treatment because of side effects. The baseline 
characteristics of the patients and the response to therapy are summarized in 
(Paper IV, Table 1). 
The baseline characteristics of the SVR and non-SVR patients were similar 
and did not differ significantly. However, patients with SVR in comparison with 
non-SVR patients were younger (39.4±12.7 years vs. 45.6±9.5 years), had 
higher ALT (123.8±151.7 U/l vs. 73.9±U/l) and lower GGT (58.9±55.2 U/l vs. 
105±120.2 U/l) levels, respectively. 
 
 
7.3.2. NS5A polymorphisms and response to combination therapy 
Overall, 29 complete NS5A sequences were proof-read twice by both strands, 
aligned, translated into proteins according to the universal code and compared 
to the reference strain HCV-J genotype 1b, accession number D90208. 
According to the classification by Enomoto et al. (1995), 17.2% (5/29) of the 
studied patients were infected with wild-type ISDR IFN resistant strains (0 
mutations), and 82.8% (24/29) of the patients were infected with intermediate 
type ISDR strains (1-3 aa mutations). None of the patients was infected with a 
mutant type strain (≥ 4 mutations). 
Examination of baseline aa sequences did not reveal statistically significant 
associations between the mean number of amino acid substitutions and 
treatment response either in the PKR-bd including ISDR, V3 or IRRDR regions, 
or in the entire NS5A for the SVR and non-SVR patients including those with 
EVR and non-EVR.  
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Specific amino acid substitutions were found at some positions depending on 
the treatment response (Paper IV, Figure 3). 
Sequence analysis of the cytoplasmic retention signal (CRS; aa 1973–1999) 
at aa position 1979 revealed D (Aspartic acid) in 91.7% (11/12) of the SVR 
patients, instead of E (Glutamic acid) in 62.5% (5/8) of the NR patients 
(p=0.018). Threonine (T) at aa position 1989 was found in 66.7% (8/12) of the 
patients with SVR, instead of Serine (S) in 75% (6/8) of the NR patients 
(p=0.028). Twenty five percent (3/12) of the patients with SVR, 14.3% (1/7) of 
the RL patients and 50% (1/2) of the ST patients carried the aa substitution 
V2333I in the nuclear localization signal (NLS; aa 2326-2334), but no corre-
lation of this mutation with therapy outcome was statistically significant 
reliable. 
Additionally, aa substitutions at the other three positions throughout the 
NS5A protein were identified for 62.5% (5/8) of the NR patients, among them 
T2107A (p=0.004), V2382A (p=0.004), and less statistically significant 
L2171V (p=0.06).  
In our study Arginine (R) at position 2283 was present in 9/12 (75%) of the 
patients with SVR, and was significantly correlated with viral loads below 
1,000,000 IU/mL (CI 35.4–84.8%; p < 0.05), instead of Proline (P) in 12/15 
(80%) of the non-SVR patients, which correlated significantly with viral loads 
higher than 1,000,000 IU/ mL, (CI 44.4–85.7%; p < 0.05). T at aa position 2319 
was found in 100% of the SVR patients (12/12), instead of Alanine (A) in 
57.1% (4/7) of the relapse patients (p=0.009). T was also found in 42.8% of the 
remaining relapsers. Amino acid substitutions throughout the NS5A protein in 
two ST patients were similar to those in SVR patients. 
 
 
7.3.3. Phylogenetic analysis 
Twenty-nine full-length NS5A nt sequences were used for phylogenetic 
analysis by ML method (Paper IV, Figure 4). 
The analysed sequences exhibited 92–94% maximal identity with HCV 1b 
strains from Japan, USA, Taiwan, China, France, Australia, Denmark, Switzer-
land, and Germany (Figure 10). 
According to the results of phylogenetic analysis, 24 group-specific nt po-
sitions were identified (Paper IV, Table 2). All of the identified nt poly-
morphisms were translated into aa. Within each subgroup there were found 
essential aa substitutions common for patients with SVR, NR and RL. Thirteen 
nt mutations were silent, but eleven nt mutations caused group-specific aa 
polymorphisms (Paper IV, Table 3). Three of these were found in the V3 
region, one in the NLS, one in the CRS region, and six occured in the non-





































































Figure 10. Phylogenetic tree, constructed by using the neighbor joining method, based 
on the analysis of 36 complete NS5A regions for HCV subtype 1b strains and 28 
sequences from GeneBank. The sequences of isolates from GeneBank are indicated 
according to accession numbers. Bootstrap values were obtained from 1000 replicates. 




8.1. Efficacy of antiviral treatment in patients with 
genotypes 1b and 3a (Papers I and II) 
The results of our study with higher (84%) SVR rate in genotype 3 and lower 
(46%) in genotype 1 patients are consistent with the results of international 
clinical and real-life settings trials, which demonstrated SVR rates of 40–52% 
for patients infected with HCV genotype 1 and over 80% for patients infected 
with HCV genotype 3 (Manns et al 2001, Fried et al 2002, Hadziyannis et al 
2004, Mauss et al 2011, Marcellin et al 2012). The reasons for this discrepancy 
are not completely clear. It may be explained by differences in viral kinetics: 
viral clearance in patients with genotype 1, who are IFN responders, is slower 
than in those infected with the other genotypes (Neumann et al 2000, Zeuzem et 
al 2001). On the other hand, differences in response to treatment are suggested 
to be explained by genetic variability between genotypes with the appearance of 
drug resistant HCV strains (Cannon et al 2008). Despite the fact that SVR(12) 
rates determined at week 12 after the end of treatment are comparable to 
standard SVR rate determined at week 24 after the end of treatment, the latter 
remains the gold standard for assessment of treatment efficacy (Martinot-
Peignoux et al 2010). In our study we used SVR determined at week 24 after 
the end of treatment.  
Several studies demonstrated that patients with a low viral load regardless of 
the genotype can achieve higher SVR compared to those who had a higher viral 
load (Navaneethan et al 2009). Although our study patients with the viral load 
below 600 000 IU/ml had higher SVR compared with patients with the viral 
load above 600 000 IU/ml, 73% and 57%, respectively, the difference did not 
reach significance (p=0.25). Nor was there found significant correlation 
between SVR and baseline levels of HCV RNA, depending on the genotype, 
either. These discrepancies may be explained in part by the fact that the cut-off 
level of low viral load is not well defined, it is variable, from 400 000 up to 
800 000 IU/ml (Manns et al 2001, Fried et al 2002, Shiffman et al 2007, 
Zeuzem et al 2006). The cut-off level set by us failed to demonstrate significant 
difference in treatment response. Nor did further statistical analysis reveal 
significant correlation between viral loads of 400 000 IU/ml and 800 000 IU/ml 
and SVR rates (p=0.1). We suggest that other factors, like genetic variability of 
the HCV genome, may be of importance.  
Our results confirm that younger age of patients is a strong predictor of 
treatment response (Saludes et al 2010, Marcellin et al 2012). Thus, SVR rate in 
the studied patients aged below 40 years was significantly higher as compared 
with that in the older patients, 76% vs. 47% (p=0.0014), respectively.  
In spite of the fact that in our study female patients showed higher SVR rate 
than male patients (69% vs. 55%, respectively), the difference was not signi-
ficant. Our finding is in line with the results of other similar studies, which also 
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failed to demonstrate significant difference between SVR rate and gender (Yu et 
al 2011, Di Marco et al 2013).  
Advanced fibrosis and cirrhosis, due to morphological changes in the liver 
that prevent optimal interactions between PegIFN/RBV treatment components 
and hepatocytes, predispose to worse treatment response (Cheng et al 2010, 
Bruno et al 2010, D’Ambrosio et al 2012). Our study failed to demonstrate 
association between stage of fibrosis and treatment outcomes in patients with 
fibrosis F0-1 and F2-3. However, none of the studied patients with compensated 
cirrhosis (F4), eight patients infected with genotype 1b and one patient with 
genotype 3a, achieved SVR. At the same time, the small number (9/121) of 
such patients did not allow us to make any relevant conclusion.  
It was shown that during antiviral therapy about 75% of patients may 
experience one or more systemic side effects and 10 to 16% of them are obliged 
to discontinue treatment due to adverse events (Arase et al 2006, McHutchison 
et al 2009). In our study 97% of the patients experienced several side effects 
with fatigue, different hematologic abnormalities and depression as the most 
prevalent ones. However, adverse events were generally mild, therefore the rate 
of treatment discontinuation was low (14%) and did not influence significantly 
SVR rate.  
In spite of the fact that 13 out of the 76 (17%) studied patients infected with 
HCV genotype 1b required dose reduction of PegIFN alfa-2a and/or RBV 
because of adverse events, adherence to treatment was rather high and did not 
affect treatment response. Moreover, nine of these patients who were obliged to 
reduce the doses of PegIFN and/or RBV achieved SVR.  
We suppose that the strict inclusion criteria of the present study (Study 
Methods) allowed the patients to be in compliance with PegIFN/RBV treatment.  
One third of patients can have extrahepatic manifestations (EHM), including 
sarcoidosis as the first symptom of CHC (Cacoub et al 2000). In the present 
study HCV 1b genotype-infected patient with systemic sarcoidosis with lung, 
liver and skin involvement was diagnosed and successfully treated with 
PegIFN/RBV at standard doses for 48 weeks. The patient achieved SVR with 
no reactivation of systemic sarcoidosis. In about 75% of cases systemic 
sarcoidosis is described as interferon-induced during the treatment of chronic 
hepatitis C (Ramos-Casals et al 2005). Presenting here our case-report of CHC 
and systemic sarcoidosis unrelated to antiviral therapy, we, like Bonnet and co-
authors (2002), speculate that HCV per se could be an antigenic trigger for 
development of sarcoidosis. We suppose that due to persistent antigenic sti-
mulation caused by chronic HCV infection, systemic sarcoidosis may present as 
an EHM of chronic hepatis C. Achievement of SVR, disappearance of liver 
granulomas at the second liver biopsy and no reactivation of systemic 
sarcoidosis confirmed our suggestion. A few cases of EHM in the study can be 
explained by the relatively young age of our population, with shorter duration of 
CHC, which predisposed to less manifestations.  
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8.2. Predictors of treatment response  
in patients with genotype 1b (Paper III) 
We conducted the present study aiming to evaluate the host and viral factors 
that are associated with treatment response in chronic hepatitis C genotype 1b 
patients. Genotype 1 was chosen as the most prevalent genotype in Estonia with 
lower response rate compared with genotypes 2 and 3.  
It was shown that age below 40 years, normal platelet count and GGT level, 
absence of or mild and moderate stages of liver fibrosis as well as absence of or 
mild inflammatory activity influenced significantly SVR and can be used as 
predictors of treatment response in patients with CHC genotype 1b. Our results 
are in line with the findings of similar studies (Mann et al 2001, Fried et al 
2002, Hadziyanis et al 2004, Marcellin et al 2012, Weich et al 2011).  
Several large prospective studies also failed to demonstrate such association 
of gender, BMI and ALT with treatment response (Manns et al 2001, Fried et al 
2002, Jacobson et al 2007, Mauss et al 2011). In a recent real-life European 
gender-oriented analysis there were no differences in response to PegIFN/RBV 
therapy between males and females. However, it was shown that different 
predictive factors in both gender groups could contribute to treatment outcomes 
(Di Marco et al 2013). The above analysis revealed absence of correlation 
between viral load and SVR, which was also discussed in the previous chapter 
8.1.   
We demonstrated that patients infected with HCV genotype 1b had a signifi-
cantly higher rate of nonresponders and relapses, which is consistent with the 
results of analogous studies (Hadziyannis et al 2004, Marcellin et al 2012, 
Weich et al 2011). 
Further we analysed the baseline host and viral characteristics for the studied 
patients with different treatment outcomes (SVR vs. NR, SVR vs. RL and NR 
vs. RL). 
It was shown that NR patients were significantly older, more overweight, 
had a more severe stage of fibrosis (F3-4) and a higher degree of inflammation 
activity, lower platelet count, and higher GGT levels in comparison with the 
SVR patients. High grade of inflammatory activity and higher GGT levels 
prevailed significantly in the NR patients as compared with the relapsers. 
Similar data have been presented by other researchers (Mann et al 2001, 
Hadziyanis et al 2004, Marcellin et al 2012, Weich et al 2011).  
There were no significant differences in the baseline characteristics between 
the SVR and the RL patients, which makes them difficult to distinguish and 
cure. Nevertheless, retrospectively it may be speculated that RL patients could 
benefit from the prolongation of antiviral treatment up to 72 weeks, as was 
shown previously (Pearlman et al 2007); however, the patients of the present 
study were treated for 48 weeks. Nowadays some of such patients, i.e. those 
with advanced fibrosis and cirrhosis (F3-4) can benefit from triple therapy with 
DAA.  
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In our study the SVR patients showed a more pronounced decrease of the 
viral load at weeks 4 and 12 as compared with both the NR and the RL patients. 
The results of our study are in line with the findings of other studies according 
to which viral kinetics at weeks 4 and 12, with the achievement of RVR and 
EVR, are reliable factors that can predict the outcome and duration of antiviral 
treatment (Pearlman et al 2007, Fried et al 2011, Marcelin et al 2012). 
Absence of hematological abnormalities (anaemia, leuco- and neutropenia), 
which were observed in the studied patients during antiviral therapy at week 12, is 
typical of non-responders and may be used as a prognostic factor of worse 
response to antiviral therapy (Navaneethan et al 2009). Escalation of the doses of 
PegIFN/RBV therapy drugs in order to overcome HCV resistance and to achieve 
high SVR rate is not recommended by the European, American and Estonian 
National Guidelines on treatment of CHC, as it does not increase SVR rate. 
 
 
8.3. Polymorphisms within the entire HCV NS5A region 
and treatment response (Paper IV) 
In our study the genetic variability of the entire NS5A coding sequence, in-
cluding the PKR-bd domain, ISDR and V3 regions, together with the less 
studied CRS, NLS and IRRDR regions, in relation to PegIFN/RBV treatment 
response in Estonian treatment-naïve patients infected with HCV genotype 1b, 
was investigated for the first time.  
 
 
8.3.1. Relationship between baseline NS5A amino acid sequences 
and treatment response 
Currently, several aa substitutions within the different regions of NS5A protein, 
specific for HCV-1b strains, are suggested as potential predictors of 
PegIFNα/RBV treatment outcome. Thus, patients infected with the wild type 
ISDR sequence identical to the Japanese HCV prototype did not respond to 
IFN-based therapy whereas patients infected with the mutant type, defined by 
four or more amino acid substitutions in this region, achieved SVR. Addi-
tionally, correlation was reported between treatment outcome and number of aa 
substitutions in the other regions within the NS5A protein of the viral isolate 
(Murphy et al 2002, Hofmann et al 2005, Muñoz de Rueda et al 2008, El-
Shamy et al 2007, 2008). However, attempts to extend this approach to 
European patients were not successful (McKechnie et al 2000, Veillon et al 
2004, Kmieciak et al 2006). 
In the present study we did not find any mutant viruses carrying four or more 
amino acid substitutions in the ISDR region. Still, our results about the distri-
bution of the wild and intermediate type ISDR strains (17.2% and 82.8%, 
respectively) were fairly similar to those reported for European (24.8% and 
63.4%, respectively) (Pasсu et al 2004) as well as for Tunisian HCV infected 
patients (26.7% and 66.7%, respectively) (Bouzgarrou et al 2009).  
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In the present study comparative analysis did not reveal a significant differ-
rence between the SVR and non-SVR patients in terms of rate of random 
mutations within the ISDR, PKR-bd, V3 or IRRDR regions, or in terms of total 
number of mutations in entire NS5A. Our data does not coincide with the 
results of several studies performed in different populations of different count-
ries, which revealed significant correlations between number of aa substitutions 
in the abovementioned NS5A regions and treatment outcome (El-Shamy et al 
2007, 2008, Kumthip et al 2011, Yano et al 2012). One explanation for this may 
be the existence of a methodological bias concerning either selection of patients, 
or therapeutic regimens (Tan et al 2001, Squadrito et al 2002). The genetic 
difference between the virus strains circulating in different regions may be 
another reason for these discrepancies (Schinkel et al 2004, Zhou et al 2011). 
However, there is still limited information available regarding the correlation of 
NS5A full-length gene polymorphisms with response to IFN based therapy. 
It seems that the polymorphism of the HCV-1b strains isolated from Euro-
pean patients, including Estonian patients, cannot be described in terms of the 
number of random mutations in comparison with the prototype strain, as has 
been suggested previously (Aus dem Siepen et al 2005, Brillet et al 2007). On 
the other hand, reliable analysis of ISDR mutations should consider a repre-
sentative number of samples of the wild, intermediate and mutant type strains in 
order to draw any relevant conclusions. 
A number of studies have focused on possible correlation between EVR and 
sequence variation within different parts of NS5A, especially the V3 region and 
its surrounding regions (Murphy et al 2002, Puig-Basagoiti et al 2005, El-
Shamy et al 2007). However, we found no difference in the number of muta-
tions in the analysed regions between the EVR and the non-EVR patients. 
Several studies showed a higher pre-treatment viral load in patients with the 
wild type ISDR sequence compared with this load in patients with the mutant 
type sequence (Enomoto et al 1996, Toyoda et al 2010). Our findings are 
consistent with the above data. It should be mentioned that the total rate of SVR 
in the present study was lower in comparison with that established in our 
previous report (Paper I). This could be explained partly by the fact that about 
90% of the patients included in our study had a higher pre-treatment viral load 
and no one of the HCV 1b infected patients had the ISDR mutant type strain. 
Moreover, we found that presence of Arginine at position 2283 correlated 
significantly with lower viral load, while Proline at the same position correlated 
with higher viral load. Further studies on a larger patient cohort will are needed 
to validate the significance of these results. 
Previous studies have reported that some specific amino acid substitutions 
are associated with treatment response. Thus, it has been proposed that patients 
infected with HCV genotype 1b who had aa mutations in NS5A at positions 
2209, 2216, 2217, 2218, 2227, 2360, and 2378, but also some others (according 
to the enumeration of the HCV-J prototype strain) achieve SVR more frequently 
than those without mutations at the abovementioned positions (Kohashi et al 
2006, El-Shamy et al 2008, Noguchi et al 2011). 
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In the present study, the association of aa substitution at specific positions in 
the NS5A protein with response to PegIFN-α plus RBV treatment was in-
vestigated as well. We did not find any difference between the sequences 
obtained from the SVR and non-SVR patients at the above described amino 
acid positions. However, we found that specific amino acid substitutions at 
positions 1989 and 2283 correlated significantly with SVR, while mutations at 
positions 1979, 2107, 2171, and 2382 were associated with non-response to 
treatment. The single amino acid substitution at position 2319 correlated with 
treatment relapse. 
Recently, three aa substitutions at positions 2268, 2260 and 2278 were 
associated with unfavorable treatment outcome in HCV-1b patients in Hong 
Kong (Zhou et al 2011). 
In contrast, our data showed that these positions were not informative for 
prognosis of treatment outcome in Estonian patients. 
All these facts can be explained, on the one hand, by genetic differencies 
between the HCV genotype 1b strains circulating in Estonia and other countries. 
On the other hand, it deserves to note some limitations of our study like the 
small number of patients in comparison with previous studies and the selection 
bias in the enrollment of patients arising from the National Guidelines for 
treatment of chronic hepatitis C.  
 
 
8.3.2. Phylogenetic analysis 
Previously, some researchers failed to show any clustering association with a 
specific pattern of response while using phylogenetic analyses of the complete 
NS5A sequence to predict treatment outcome (Jardim et al 2009). 
In the present study, in phylogenetic analysis 1b strains were divided into 4 
groups (Paper IV, Figure 4), considering our previous suggestions about several 
separate introductions of the 1b strain in Estonia (Tallo et al 2007). For the first 
time we segregated the isolated strains into six subgroups mainly according to 
treatment outcome (Paper IV, Figure 4). Further, the obtained 1b sequences 
were translated into proteins and aligned according to the mentioned groups.  
Phylogenetically, 24 group-specific nucleotide positions were identified 
(Paper IV, Table 2), of these thirteen nt mutations were silent and eleven nt 
mutations caused group-specific aa polymorphisms (Paper IV, Table 3).  
The results of our study after validation on studies based on large data sets 
can be recommended to use as predictors of treatment response in Estonian 
treatment-naïve patients monoinfected with HCV genotype 1b. 
We believe that the results of our study of genetic variability within the 
NS5A region of HCV genome could shed light on unsatisfactory cure rates, 
especially in treatment-naïve patients monoinfected with HCV genotype 1b in 
the face of viral resistance and could help to improve treatment outcome in such 
patients in the future.   
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8.4. Considerations and limitations related  
to the study design 
Our study, conducted in one of the five centers in Estonia providing treatment 
of CHC, is the first one reflecting the experience of PegIFN/RBV therapy for 
treatment–naïve patients monoinfected with CHC genotypes 1b and 3a in 
routine clinical practice. Co-existence of HCV/HIV infections is a challenge for 
the health care system. HIV/HCV coinfected patients, which is an issue of 
serious concern in Estonia (Uuskula et al 2007), were not included in the study 
as they are usually referred to infectious disease clinics located in several 
Estonian counties. A specific population of IDUs having high rate of HIV, HCV 
and HBV coinfections was excluded from the study, too. 
Owing to the use of strict selection criteria, we were able to form a unique 
study population which differed from analog patient cohorts of other studies 
(Manns et al 2001, Fried et al 2002, Hadziyannis et al 2004, Mauss et al 2011, 
Marcellin et al 2012). Our patients were characterized as follows: they were 
relatively young, with a mean age of 43 years for genotype 1b infected patients 
and 35 years for genotype 3a infected patients.  
Baseline ultrasound-guided transcutaneous liver biopsy was performed to all 
study patients (100%), which is a higher percentage that those reported in other 
real-life studies (Mauss et al 2011, Bourliere et al 2012). 
The proportion of patients (75%) without or with a mild stage of fibrosis 
(F0-1) was quite large. Taking into consideration the above circumstances and 
owing to the natural course of HCV infection, it was unlikely to expect a high 
number of patients with advanced fibrosis and cirrhosis (F3-4), which definitely 
diminished the power of statistical analysis.   
One of the limitations of this study, which is an issue of discussion, was the 
relatively small number of patients in comparison with other randomized and 
real-life setting clinical trials. This could in some cases have diminished the 
power of statistical analysis in detecting significant associations between 
different baseline variables and SVR. Yet further delay in the analysis of our 
data for statistics related reasons would have rendered our study of less 
importance, especially in the era of DAA.  
Another limitation may be that we did not use several host genetic factors, 
like polymorphisms of the human IL28B gene, which is known as a very 
important predictor of treatment response to PegIFN/RBV therapy in patients 
infected with HCV genotype 1 (Ge et al 2009, Par et al 2011, 2014). This can be 
explained by the fact that at the time of conducting the study the relevant test 






8.5. Future research 
Despite the fact that the incidence of new HCV infections has decreased 
worldwide, the burden of HCV-related diseases is expected to increase. Triple 
therapy with PIs (BOC and TVR) has been reported to increase SVR rates up to 
63–75% as compared to the standard dual therapy in patients with CHC. In 
Estonia, the SOC for treatment of HCV genotype 1 was changed from the 
beginning of 2014 when both of these medications were approved for use in 
combination with PegIFN/RBV for treatment of CHC genotype 1-infected 
treatment-naïve and experienced patients with advanced liver fibrosis or com-
pensated cirrhosis.  
However, the using of DAAs can lead to the emerging problem of drug 
resistance due to so-called resistance-associated amino acid variants of the 
virus. The prevalence of these resistance mutations in patients treatment-naive 
for PIs has not been fully characterized. 
Moreover, the frequency of resistance can vary between the HCV subtypes, 
being twice as high in patients with subtype 1a compared with subtype 1b. 
Although subtype 1b has remained predominant, the introduction of subtype 1a 
into the populations of IDUs and blood donors has been observed in Estonia at 
least since 2007 (Tallo et al 2011). Thus, we could expect an increase in the 
number of patients infected with this subtype. Taking into consideration the 
above circumstances, we are going to assess the efficacy of triple therapy with 
PIs in patients infected with both HCV subtypes, 1a and 1b, and to compare it 
with existing dual therapy. Other noteworthy issues of our future plans are study 
of the presence of primary PIs resistance mutations and follow up of the 
emergence of PIs resistant variants during triple therapy in order to evaluate 
their impact on treatment response. 
In Estonia there is no state or regional standard or national policy on HCV 
prevention or a general anti-HCV screening programme. Only two specific 
subgroups, the blood donors and the prisoners, are screened on a regular basis. 
The seroprevalence of HCV infection has been well studied only in specific 
study populations, like IDUs, inmates, hemodialysis and oncohematologic 
patients (Tefanova et al 2005, 2006, Uuskula et al 2007). As new treatment 
options are becoming available, there will arise the need to quantify the burden 
of chronic HCV infection at the national level. The data to be obtained can 
optimize the cost-effectiveness of CHC treatment in Estonia and hence reduce 








To our knowledge, this is the first systematic study aimed to assess the efficacy 
of PegIFN/RBV treatment and to evaluate the host and virus factors predicting 
the outcome of antiviral therapy in treatment-naive patients with CHC in 
clinical practice in Estonia. 
  
1.  The efficacy of PegIFN/RBV therapy was strongly predetermined by the 
HCV genotype and younger age of the studied patients. The SVR rate for 
patients infected with HCV genotype 1b was significantly lower compared 
with SVR rate for patients infected with HCV genotype 3a.  
 
2.  Age below 40 years, absence of or mild and moderate liver fibrosis, absence 
of severe inflammatory activity, normal platelet count and normal GGT level 
with pronounced changes in viral kinetics at weeks 4 and 12 were valuable 
predictors of treatment response in treatment-naïve patients with the chronic 
hepatitis C 1b genotype. The non-responders differed significantly from the 
patients with SVR in terms of almost all pre- and on-treatment studied 
parameters. Regarding their characteristics the relapsers were very similar to 
the patients with SVR.  
 
3.  Study of amino acid polymorphisms failed to demonstrate association 
between number of mutations within the either entire NS5A protein of HCV 
or its different known functional regions, and different types of response 
(SVR, non-response or relapse) to PegIFN/RBV therapy in treatment-naïve 
patients with the chronic hepatitis C 1b genotype.  
 
4.  Correlation between treatment response (SVR, non-response or relapse) and 
specific amino acid substitutions at different previously not described 
positions within the NS5A protein was identified. Phylogenetic analysis 
revealed 11 novel aa substitutions in the full-length NS5A protein, which 
can be used as tags to predict treatment response in Estonian treatment-naïve 










10. SUMMARY IN ESTONIAN 
Krooniline C-hepatiit: ravitulemusi prognoosivad tegurid  
Eesti patsientidel 
C-hepatiidi viirusest (HCV) põhjustatud krooniline hepatiit on suur tervishoiu-
probleem, sest haigestunud võib olla ligikaudu 2,3% maailma rahvastikust. 
Aastas sureb C-hepatiidist tekkinud maksatsirroosi ja maksarakk-kasvaja tõttu 
umbes 350 000 inimest. Euroopas erineb C-hepatiidi levimus piirkonniti. Eestis 
on C-hepatiidi viirusega nakatunud hinnanguliselt vähemalt 1% rahvastikust. 
C-hepatiidi viirus kuulub Flaviviridae sugukonda ja Hepacivirus’e perekon-
da. Sellel viirusel on seitse genotüüpi ja üle 60 alltüübi. Eestis on enam levinud 
1b genotüüp, millele järgneb 3a genotüüp. HCV genotüübi teadmisel on klii-
niline tähendus, st genotüübist sõltub kroonilise maksahaiguse kulg, viirus-
vastase ravi tulemused ja ka kestus. 
Viirusvastane vaktsiin ja nakatumisjärgne profülaktika puuduvad. Ägeda C-
hepatiidiga haigetest tervistub 15%, ülejäänutel tekib krooniline C-hepatiit. 
Krooniline C-hepatiit võib kulgeda vaevusteta kuni maksatsirroosi tekkeni. 
Maksatsirroosi tekkeks kulub 10−30 aastat nakatumisajast. Maksatsirroosist 
omakorda võib 4% haigetel aastas tekkida maksarakk-kasvaja. 
Alfa-peginterferoon (alfa-2a-peginterferoon ja alfa-2b-peginterferoon) ja 
ribaviriin on aastaid olnud kroonilise C-hepatiidi standardravi. Viirusvastase 
ravi eesmärk on C-hepatiidi viiruse kadumine verest ehk C-hepatiidi viiruse 
RNA (HCV RNA) puudumine veres. Viirusvastase ravi tõhususe kriteerium on 
püsiv viirusvastus – HCV RNA on negatiivne 24 nädalat pärast viirusvastast 
ravi. 
Viirusvastase ravi tõhusus tuleneb genotüübist. Teise ja kolmanda geno-
tüübiga patsientidest saavutab püsiva viirusvastuse üle 80%, esimese geno-
tüübiga patsientidest aga vaid ligikaudu 50%. 
Viirusvastase ravi tõhusust mõjutavad mitu patsiendist olenevat ja ka mitu 
C-hepatiidi viirusest tulenevat tegurit. Need on patsiendi vanus, sugu, amino-
transferaaside sisaldus veres, maksafibroosi raskusaste ja põletiku aktiivsus 
maksakoes. Viiruse genotüübist ja viirusekogusest sõltub viirusvastasele ravile 
allumise tõenäosus ning ravi kestus. HCV genoomi muutlikkus võib samuti 
mõjutada alfa-peginterferooni ja ribaviriiniga ravimise tõhusust. Näiteks viiruse 
mittestruktuurvalk NS5A on vajalik viiruse replikatsiooniks ja tema erinevate 




Käesoleva töö eesmärk oli uurida varem viirusvastast ravi mittesaanud 
(nn ravinaiivsetel) kroonilise C-hepatiidiga patsientidel peremeesorganismist ja 
C-hepatiidi viirusest tulenevaid tegureid, et prognoosida alfa-peginterferooni 
ning ribaviriiniga ravimise tõhusust. 
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Uurimistöö eesmärgid olid järgmised: 
1. hinnata alfa-peginterferooni ja ribaviriiniga ravimise tõhusust Eestis varem 
viirusvastast ravi mittesaanud kroonilise C-hepatiidi esimese ja kolmanda 
genotüübiga patsientidel (I ja II artikkel); 
2.  määrata peremeesorganismist ja C-viirusest tulenevad tegurid, mis mõju-
tavad viirusvastase ravi tõhusust kroonilise C-hepatiidi 1b genotüübiga 
patsientidel nii enne viirusvastast ravi kui ka ravi ajal (III artikkel); 
3.  analüüsida kroonilise C-hepatiidi 1b genotüübiga patsientidel HCV mitte-
struktuurvalgu NS5A muutlikkuse ja ravitulemuse vahelisi seoseid (IV 
artikkel). 
 
Uuritav materjal ja meetodid 
Alates 2005. aasta veebruarist kuni 2011. aasta märtsini uuriti kokku 121 (I ja II 
artikkel), 76 (III artikkel) ja 29 (IV artikkel) varem viirusvastast ravi mitte-
saanud kroonilise C-hepatiidiga patsienti. Uuring tehti Lääne-Tallinna Kesk-
haiglas. 
Kroonilise C-hepatiidi diagnoosimine, viirusvastane ravi ja patsiendi jälgi-
mine viirusvastase ravi ajal toimusid kroonilise C-hepatiidi Eesti ravijuhendite 
järgi. Enne uuringu alustamist allkirjastasid kõik patsiendid nõusolekuvormi ja 
uuringu kiitis heaks Tallinna Meditsiiniuuringute Eetikakomitee. 
Kliinilise vere, biokeemiliste ja autoantikehade näitajad määrati Lääne-
Tallinna Keskhaigla diagnostikakliiniku laboris. HCV antikehad, HCV RNA 
genotüüp ja HCV RNA viirusekogus määrati Lääne-Tallinna Keskhaigla HIV 
nakkuse referentslaboris. 
HCV RNA viirusekogus määrati enne ravi alustamist, 4., 12., 24. ja 
48. ravinädalal ning 24. nädalal pärast viirusvastast ravi. Kõikidelt patsientidelt 
võeti enne viirusvastase ravi alustamist Lääne-Tallinna Keskhaigla radio-
loogiaosakonnas ultrahelikontrolli all transkutaanne maksabiopsia. Maksakoes 
hinnati fibroosi staadiumi ja põletiku raskusastet Metaviiri skoori järgi, 
histoloogiline uuring tehti Põhja-Eesti Regionaalhaigla patoloogiaosakonnas. 
NS5A polümorfismi uurimiseks ekstraheeriti HCV RNA, sünteesiti cDNA, 
sekveneeriti RT-PCR ja HCV genoom terves NS5A piirkonnas (1341 nukleo-
tiidi) ning tehti sekventside fülogeneetiline analüüs. NS5A järjestused tõlgen-
dati valkudeks universaalse koodi järgi ja võrreldi 1b genotüübi referentstüvega. 
Kõik järjestused anti hoiule NCBI GenBanki nukleotiidide järjestuste andme-
baasi registreerimisnumbritega JX022751-JX022779. 
Sõltumata viiruse genotüübist manustati kõigile patsientidele viirusvastase 
ravi käigus alfa-2a-peginterferooni 180 μg kord nädalas ning ribaviriini 
kehakaalu ja genotüübi alusel. Esimese genotüübi puhul manustati ribaviriini 
alla 75 kg kehakaaluga patsientidele 1000 mg ja kehakaaluga üle 75 kg 
1200 mg ööpäevas. Teise ja kolmanda genotüübi puhul oli ribaviriini annus 
800 mg ööpäevas. 
Viirusvastase ravi kestus 1b genotüübiga patsientidel oli 48 nädalat, teise ja 
kolmanda genotüübi puhul 24 nädalat. Patsiendi ravi oli tulemuslik juhul, kui 
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saavutati püsiv viirusvastus ehk kui HCV RNA oli negatiivne 24 nädalat pärast 
ravi lõppu. 
Statistiliseks analüüsiks kasutati χ2-testi, Fisheri täpset testi ja Studenti testi. 
Kvantitatiivseid näitajaid väljendati nagu keskväärtus ±SD. Näitajate korrelat-
siooni hinnati Pearsoni või Spearmani korrelatsioonikoefitsiendi abil. Statistili-
selt oluliseks peeti kahepoolset P väärtust, mis oli väiksem kui 0.05. Usaldus-
vahemik (CI) oli 95%. 
Peremeesorganismist ja viirusest tulenevate ravi tõhusust mõjutavate tegurite 




1. Viirusvastase ravi tõhusus esimese ja kolmanda genotüübiga patsientidel 
(I ja II artikkel) 
60.3% patsientidest saavutas püsiva viirusvastuse. Esimese genotüübiga pat-
sientidel oli püsiva viirusvastuse saavutamine statistiliselt väiksem kui kolman-
da genotüübiga patsientidel (vastavalt 46.1% vs. 84.4%). 
Ravile mitteallunute arv, sh mittevastajad (non-responder, NR) ja tagasi-
langejad (relapser, RL), oli esimese genotüübi rühmas suurem kui kolmanda 
genotüübi rühmas (vastavalt 19.7% vs. 2.2% ja 17.1% vs. 4.4%). 
Mitmemõõtmeline logistiline regressioonanalüüs näitas, et ainult kolmas 
genotüüp ja patsiendi vanus (40 aastat või alla selle) suurendasid sõltumatult 
ning oluliselt püsiva viirusvastuse saavutamist. Sellised tegurid nagu viiruse-
kogus, maksafibroosi raskusaste ja meessugu ei korreleerunud mitmemõõtme-
lises logistilises regressioonanalüüsis oluliselt püsiva viirusvastusega. 
Peaaegu kõigil patsientidel esines viirusvastase ravi kõrvaltoimeid, millest 
sagedasemad olid väsimus (90%) ja laborianalüüsides neutropeenia (79%). Esi-
mese genotüübiga patsientidest vajas 17% kõrvaltoimete tõttu alfa-2a-peginter-
ferooni või ribaviriini annuste vähendamist. Nendest üheksa patsienti saavutas 
püsiva viirusvastuse, kolm patsienti osutusid mittevastajateks ja üks patsient 
katkestas ravi. 
Kõigist uuritud patsientidest 14% katkestas ravi eelkõige kõrvaltoimete tõttu. 
Uuringus osalenud 25-aastane meespatsient, kellel diagnoositi krooniline 1b 
genotüübiga C-hepatiit koos süsteemse sarkoidoosiga, saavutas püsiva ravi-
vastuse. Viis kuud hiljem tehtud korduval maksapunktsioonil maksagranu-
loomid puudusid. 
 
2. Ravivastust prognoosivad tegurid 1b genotüübiga patsientidel  
(III artikkel) 
Esimese genotüübiga patsientidest saavutas püsiva viirusvastuse 50% (76). Ra-
vile mitteallujaist (38/76) oli 24% mittevastajaid (NR) ja 20% oli tagasilange-
jaid (RL); viis patsienti katkestas ravi kõrvaltoimete tõttu. 
Ühemõõtmelise regressioonanalüüsiga avastati viis põhiparameetrit, mis 
mõjutasid oluliselt püsivat viirusvastust: vanus alla 40 aasta, referentsväärtuses 
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trombotsüütide arv ja gammaglutamüüli transferaas, maksafibroosi puudumine 
või kerge kuni mõõdukas fibroosi aste, aktiivse maksapõletiku puudumine või 
kerge aktiivsus. Korrelatsioone püsiva viirusvastuse, kehamassiindeksi, ravi-
eelse viirusekoguse ega alaniini aminotransferaasi väärtuse vahel ei esinenud. 
Mitmemõõtmelise logistilise regressioonanalüüsiga ei avastanud neid para-
meetreid sõltumatute prognoosivate teguritena. 
Enne ravi alustamist analüüsiti peremeesorganismist ja viirusest tulenevaid 
tegureid erinevates rühmades: SVR vs. NR, SVR vs. RL ja NR vs. RL. Mitte-
vastajad (NR) olid statistiliselt vanemad ja ülekaalulisemad ning nende seas oli 
rohkem raskema maksafibroosi ja suurema aktiivsuse, väiksema trombotsüütide 
arvu ning suurema gammaglutamüüli transferaasi väärtustega patsiente kui 
püsiva viirusvastusega patsientide seas. Tagasilangejad (RL) sarnanesid püsiva 
viirusvastuse saavutanutega. 
Püsiva viirusvastusega patsientidel oli aga viirusekoguse vähenemine 4. ja 
12. ravinädalal statistiliselt olulisem võrreldes mittevastajate ja tagasilange-
jatega. 
 
3. Aminohapete polümorfism NS5A regioonis ja ravivastus (IV artikkel) 
17% patsientidest esinesid ISDR-i piirkonnas metsiku tüübiga (0 mutatsiooni) ja 
83% patsientidest vahetüübiga (1–3 aa mutatsiooni) tüved. Ükski patsient ei 
olnud nakatunud muteeruva tüübiga (≥ 4 mutatsiooni). 
Geneetiline analüüs ei näidanud ei püsiva viirusvastusega patsientidel ja 
ravile mittevastanud patsientidel statistiliselt olulisi seoseid aminohapete 
asenduste numbrite ning ravivastuse vahel ISDR-i, PKR-bd, V3 ja IRRDR-i 
piirkonnas ega NS5A valgus. Aminohapete asendused T1989 ja R2283 kor-
releerusid oluliselt püsiva viirusvastusega, kuid E1979, A2107, V2171 ja 
A2382 esinesid mittevastajail. Tagasilangejail avastati T2319A asendus. 
Fülogeneetilise analüüsi abil isoleeritud tüved rühmitati ravitulemuse alusel 
nelja rühma. Avastati 24 spetsiifilist nukleotiidide positsiooni. 13 mutatsiooni 
olid vaikivad, kuid erineva vastusega rühmades leiti 11 nukleotiidide mutat-
siooni. Kolm mutatsiooni avastati V3 piirkonnas, ühekaupa NLS-i ja CRS-i 




1. Viiruse genotüüp ja vanus alla 40 aasta olid viirusvastase alfa-peginter-
ferooni ning ribaviriiniga ravimise tõhususe olulised prognoosivad tegurid. 
Kroonilise C-hepatiidi 1b genotüübiga patsiendid allusid ravile halvemini 
kui 3a genotüübiga patsiendid. 
2. Vanus alla 40 aasta, maksafibroosi puudumine või kerge kuni mõõdukas fib-
roos, aktiivse maksapõletiku puudumine või kerge aktiivsus, referents-
väärtuses trombotsüütide arv ja gammaglutamüüli transferaasi väärtus ning 
viirusekoguse vähenemine 4. ja 12. ravinädalal olid kroonilise C-hepatiidi 1b 
genotüübiga ravinaiivsetel patsientidel ravivastuse kindlad kriteeriumid. 
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Ravile mittevastajad (non-responder) erinesid viirusvastase ravi tõhusust 
mõjutavate tegurite poolest oluliselt püsiva viirusvastusega patsientidest nii 
enne viirusvastast ravi kui ka ravi ajal. Tagasilangejad (relapser) sarnanesid 
püsiva viirusvastuse saavutanud patsientidega. 
3. Aminohapete polümorfismi uuringus ravinaiivsetel kroonilise C-hepatiidi 1b 
genotüübiga patsientidel puudus seos nii HCV terve NS5A valgu kui ka 
NS5A valgu eri piirkondade mutatsioonide arvu ning alfa-peginterferooni ja 
ribaviriini ravivastuse (püsiv viirusvastus, non-response või relapse) vahel. 
4. Leiti korrelatsioon ravivastuse (püsiv viirusvastus, non-response või relapse) 
ja NS5A valgu varem mittekirjeldatud spetsiifiliste aminohapete asenduste 
vahel. Fülogeneetilisel analüüsil selgus 11 uut aminohapete asendust terves 
NS5A valgus, millele tuginedes võib prognoosida ravi tõhusust Eesti 
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